

C. DANIEL MULLINS, PHD

University of Maryland School of Pharmacy
Pharmaceutical Health Services Research Department
220 Arch Street, 12th Floor
Baltimore, MD 21201
(410) 706-0879 (phone)
email: Daniel.Mullins@rx.umaryland.edu

EDUCATION

PhD in Economics, Duke University, 1994
BS in Economics, M.I.T., 1986

EMPLOYMENT

UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY

Chair, Pharmaceutical Health Services Research (PHSR) Dept
Interim Chair, PHSR Dept
Professor
Chair, PHSR Dept
Associate Director, Center on Drugs & Public Policy
Associate Professor/Graduate Program Director
Assistant Professor

July 2014 – present
October 2013 – June 2014
July 2003 - present
April 2003 – July 2008
December 2000 - present
July 1999 - June 2003
July 1995 - June 1999

UNIVERSITY OF NORTH CAROLINA SCHOOL OF PHARMACY

Director of Graduate Studies
Assistant Professor

July 1994 - July 1995
July 1993 - July 1995

AWARDS

- 2017 ISPOR Marilyn Dix Smith Leadership Award
- 2017 UMB Martin Luther King Faculty Diversity Award
- 2014 UMB Co-Researcher of the Year
- 2013 UMB Champion of Excellence
- 2013 University System of Maryland Wilson H. Elkins Professorship
- 2013 Association of Black Cardiologists Dr. Daniel D. Savage Memorial Science Award
- 2008 International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Service Award
- 2007 Dr. Patricia Sokolove Outstanding Mentor Award (University of Maryland Baltimore Graduate Student Association campus-wide Award)
- 2006 International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Service Award
- 2002 ISPOR 5th Annual European Congress Best Podium Presentation
- 2002 Drug Information Association (DIA) Outstanding Service Award
- 1998 Faculty Development Award in Pharmacoeconomics. Provides \$40,000/year for 2 years
Source: Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation

GRANTS

- “Improving FDA Health Communications with Older Women Regarding FDA Regulated Products – Phase 1b.” Source: US FDA 2019; \$432,086 (Principal Investigator).
- “Building Trust to Enhance Diversity in Aging Research” Source: **NIH/NIA (R24 AG063728)** 2019; \$2,083,046 (Administrative Principal Investigator; mPI = Jay Magaziner, PhD, MSHyg).
- “Capacity Building for a Learning PCOR System.” Source: PCORI 2019; \$250,000 (Principal Investigator).
- “Johns Hopkins Institute for Clinical and Translational Research” Source: **NIH/NCATS (UL1TR003098)** 2019; \$15,388,930 (Co-Lead for Community & Collaboration Core; Principal Investigator = Daniel Ford, MD, MPH).
- “Integrated Tele-Sleep Mobile Platform” Source: Medical Technology Enterprise Consortium 2019; \$4,000,000 (Co-Investigator; Principal Investigator = Emerson Wickwire, PhD).
- “Agency for Health Research and Quality (AHRQ) R24 Conference Grant Program” Source: **AHRQ (R13HS026092)** 2018; \$97,994 (Principal Investigator).
- “Peer Review: Mapping and Resourcing Patient and Stakeholder Engagement Along 10-Step PCOR Continuum Framework.” Source: PCORI (Modification of contract ME-1409-20792) 2018; \$58,126 (Principal Investigator).
- “Family Social Inclusion: Learning from Brazil to Baltimore.” Source: Robert Wood Johnson Foundation 2018; \$239,973 (Co-Investigator; Principal Investigator = Yolanda Ogbolu, PhD, CRNP-Neonatal, FAAN).
- “PCOR Training for Minority Practitioners and their Patients.” Source: PCORI 2018; \$187,392 (Co-Investigator; Principal Investigator = Catherine Cooke, PharmD).
- “Improving FDA Health Communications with Older Women Regarding FDA Regulated Products.” Source: US FDA 2018; \$162,000 (Principal Investigator).
- “Center for Patient-Focused Value Assessment.” Source: PhRMA Foundation 2018; \$500,000 (Co-Investigator; Principal Investigator = Susan dosReis, PhD).
- “PREPARE: Pragmatic Randomized Trial Evaluating Preoperative Antiseptic Skin Solutions in Fractured Extremities.” Source: PCORI (contract PCS-1609-36512) 2017; \$10,799,706 (Co-Lead for Stakeholder Engagement; Principal Investigator = Gerard Slobogean, MD, MPH).
- “Aqueous-PREP: A Pragmatic Randomized trial Evaluating Pre-operative aqueous antiseptic skin solutions in open fractures.” Source: US Department of Defense - Award W81XWH-17-1-0702.” PCORI 2017; \$2,990,463 (Co-Investigator; Principal Investigator = Gerard Slobogean, MD, MPH).
- “Direct Medical Costs of Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease in the United States.” Source: Alpha-1 Foundation 2017; \$157,753 (Principal Investigator).
- “Co-developing Sustainable Learning Health Care Communities using CBPR.” Source: Merck 2017; \$250,000 (Principal Investigator).
- “A Randomized Pragmatic Trial Comparing the Complications and Safety of Blood Clot Prevention Medicines Used in Orthopedic Trauma Patients.” Source: PCORI (contract PCS-1511-32745) 2016; \$11,198,854 (Co-Lead for Stakeholder Engagement; Principal Investigator = Robert O'Toole, MD, TRD).
- “Alpha-1 Antitrypsin Deficiency Costs and BIA.” Source: AlphaNet, Inc. 2016; \$191,515 (Principal Investigator).
- “Integration of cancer health activities into African American churches.” Source: American Cancer Society 2016; \$1,667,000 (Subcontract PI; Principal Investigator = Cheryl L. Holt, PhD).
- “Community-Academic Partnerships to Improve Birth Outcomes: B'more for Healthy Babies Mondawmin.” Source: American Association of Medical Colleges 2016; \$300,000 (Co-Investigator; Principal Investigator = Wendy G. Lane, MD, MPH).
- “Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Trial.” Source: PCORI (contract PCS-1403-12804) 2015;

- \$11,893,395 (Subcontract PI for Stakeholder Engagement; Principal Investigator = Justin Bekelman, MD).
- “Maryland Faith Community Health Network” Source: Multiple Foundations 2015; \$25,000 (Subcontract PI as Head of Internal Evaluation; Principal Investigator = Vincent DeMarco).
- “Mapping and Resourcing Patient and Stakeholder Engagement Along 10-Step PCOR Continuum Framework.” Source: PCORI (contract ME-1409-20792) 2015; \$1,214,861 (Principal Investigator).
- “PCOR Training for “Non-usual Suspects: A Program for Rare Disease Patient Advocates” Source: PCORI 2015; \$248,937 (co-Investigator; Principal Investigator = Eleanor Perfetto, RPh, PhD).
- “Publication of Studies on Real-World Evidence: Journal Editor Perceptions and Approaches.” Source: National Pharmaceutical Council 2015; \$148,251 (Co-Principal Investigator with Eleanor M. Perfetto, PhD).
- “Modeling long-term versus short-term ICERs by incorporating pricing dynamics.” Source: Novartis 2015; \$107,588 (Principal Investigator).
- “Genomic Diagnosis and Individualized Therapy of Highly Penetrant Genetic Diabetes.” Source: **NIH/NHGRI (U01HG007775)** 2014; \$3,732,721 (co-Investigator; Principal Investigator = Toni Pollin, PhD).
- “Methods for Prioritizing Surrogate Desired Health Outcomes for Patients.” Source: PCORI (contract ME-1306-01511) 2014; \$937,520 (co-Investigator; Principal Investigator = Susan dosReis, PhD).
- “Patient-Centered Research for Outcomes, Effectiveness, and Measurement (PROEM): A Center of Excellence in Comparative Effectiveness and Patient-Centered Outcomes Research Training.” Source: PhRMA Foundation 2014; \$250,000 (Co-Investigator; Principal Investigator = Eleanor Perfetto, RPh, PhD).
- “PATIENTS: PAPatient-centered Involvement in Evaluating effectiveNess of TreatmentS.” Source: **AHRQ (R24HS022135)** 2013; \$4,940,615 (Principal Investigator).
- “West Baltimore Primary Care Access Collaborative (WBPCAC) Health Enterprise Zone (HEZ).” Source: State of Maryland 2013; \$5,000,000 (Subcontract PI as Head of Internal Evaluation; Principal Investigator = Samuel L. Ross, MD, MS).
- “Promise Heights: A Promise Neighborhood in Baltimore, MD.” Source: **US Department of Education (U215P120025)** 2013; \$499,735 (Co-Investigator; Principal Investigator = Bronwyn Mayden, MSW).
- “GPC Endocrine-Metabolic (Diabetes) Consortium.” Source: CMTP 2013; \$30,000 (Principal Investigator).
- “Heterogeneous Treatment Effects: DNA vs. MSA.” Source: National Pharmaceutical Council 2012; \$185,562 (Principal Investigator).
- “Cancer Related Bone Metastasis.” Source: Amgen Inc. 2011; \$568,950 (Co-Investigator; Principal Investigator = Arif Hussain, MD).
- “Interviews to Identify Evidence for Eliciting the Hard to Reach Patient's Perspective in PCOR.” Source: PCORI (contract PCORI-SOL-PCWG-002) 2011; \$125,000 (Principal Investigator).
- “Modifying Contact Precautions for MRSA in Extended Care.” Source: **AHRQ (R18HS019979-01A1)** 2011; (Economist; Principal Investigator = Mary-Claire Roghmann, MD, MS).
- “Colon Cancer SEER-Medicare CER: HEOR.” Source: Bayer HealthCare Pharmaceuticals 2011; \$398,700 (Principal Investigator).
- “Prostate Cancer SEER-Medicare CER: HEOR.” Source: Bayer HealthCare Pharmaceuticals 2011; \$393,300 (Co-Principal Investigator; Principal Investigator = Eberechukwu Onukwugha, PhD).
- “Treatment Selection and CER of Liver Cancer Treatment.” Source: Bayer HealthCare Pharmaceuticals 2010; \$399,999 (Co-Principal Investigator; Principal Investigator = Fadia T. Shaya, PhD, MPH).

- “Interpreting IV Estimates with Treatment Effect Heterogeneity: ACE/ARBs & Race.” Source: **NIH/NIA (RC4AG038635)** 2010; \$1,458,033 (co-Investigator; Principal Investigator = John M. Brooks, PhD).
- “Do Bayesian Adaptive Trials Offer Advantages for CER?” Source: **NIH/NHLBI (RC4HL106363)** 2010; \$1,499,866 (Principal Investigator).
- “The Value of Atorvastatin over the Product Life Cycle.” Source: Pfizer 2010; \$84,000 (Principal Investigator).
- “Cost Study of Linezolid versus Vancomycin among Hospitalized Patients.” Source: Pfizer 2010; \$235,224 (Principal Investigator).
- “FDA/CDER University of Maryland Basic Topics in Statistics: ANOVA, ANCOVA, Linear Regression, Logistics Regression and Survival Analysis.” Source: Food and Drug Administration (FDA) 2010; \$30,000 (Principal Investigator).
- “Patient Flow and VTE Incidence among Colon Cancer Patients.” Source: Sanofi-Aventis 2009; \$237,600 (Principal Investigator).
- “Analysis of the Baltimore Community Health Partnership (CHP): Feasibility and Effectiveness of Baltimore Community-based Engagement in MTM Adherence.” Source: Sanofi-Aventis 2009; \$244,026 (Multiple Principal Investigators = C. Daniel Mullins, PhD and Fadia T. Shaya, PhD, MPH).
- “The Comparative Effectiveness of Tiotropium Plus Long-Acting β 2-agonist in the Treatment of Chronic Obstructive Pulmonary Disease at the Veterans Affairs Maryland Health Care System.” Source: Novartis 2009; \$132,384 (Co-Investigator; Principal Investigator = Ebere Onukwugha, PhD).
- “Treatment and Survival among Men Diagnosed with Prostate Cancer: An examination of newer management strategies and therapies.” Source: Sanofi-Aventis 2009; \$421,809 (Multiple Principal Investigators = C. Daniel Mullins, PhD and Ebere Onukwugha, PhD).
- “Treatment Patterns, Outcomes, and Costs Related to Colon Cancer.” Source: Sanofi-Aventis 2009; \$319,337 (Multiple Principal Investigators = C. Daniel Mullins, PhD and Ebere Onukwugha, PhD).
- “The Economic Burden of Overactive Bladder Symptoms.” Source: Pfizer, Inc. 2008; \$113,605 (Co-Investigator; Principal Investigator = Ebere Onukwugha, PhD).
- “FDA/CDER University of Maryland Basic Topics in Statistics: ANOVA, ANCOVA, Linear Regression, Logistics Regression and Survival Analysis.” Source: Food and Drug Administration (FDA) 2008; \$30,000 (Principal Investigator).
- “Response to Medicare Reimbursement Policy Change by Minority and All ESRD Patients.” Source: **NIH/NIA (R21AG033791)** 2008; \$325,433 (Principal Investigator).
- “Computerized Decision Support at the Time of a Prescription.” Source: Department of Veterans Affairs Health Services Research and Development Service (HSR&D) 2008; \$110,810 (Co-Investigator; Principal Investigator = Sylvain DeLisle, MD, MBA).
- “Maryland Men’s CardioVascular Health Promotion Program (MVP).” Source: CareFirst BlueCross BlueShield 2008; \$1,000,000 (Co-Investigator; Principal Investigator = Fadia T. Shaya, PhD, MPH).
- “Treatment Patterns, Costs, and Outcomes across Various Cancer Sites.” Source: Sanofi-Aventis 2007; \$690,000 (Principal Investigator).
- “Improving Quality through Health IT: Testing the Feasibility and Assessing the Impact of Using Existing Health IT Infrastructure for Better Care Delivery.” Source: **AHRQ HHSA290200600022, Task Order #3** 2007; \$393,457 (Consultant; Principal Investigator = Romana Hasnain-Wynia, PhD).
- “Antithrombotic Therapy Outcomes Research Compendium.” Source: Pfizer 2007; \$129,357 (Principal Investigator).
- “Linezolid vs. Vancomycin Outcomes among MRSA Patients.” Source: Pfizer 2007; \$322,676 (Principal Investigator).
- “White Paper on Cost/QALY Threshold.” Source: GlaxoSmithKline 2007; \$55,000 (Principal Investigator).

- “Health care utilization and spending among a commercially-insured population using antipsychotics: the influence of drug characteristics.” Source: Bristol-Myers Squibb 2007; \$144,160 (Co-Investigator; Principal Investigator = Linda Simoni-Wastila, RPh, PhD).
- “Barriers to Preemptive Kidney Transplantation.” Source National Kidney Foundation 2007; \$25,000 (Co-Investigator; Principal Investigator = Françoise G. Pradel, PhD).
- “Adverse Event Costs in Osteoarthritis NSAID Users.” Source: Novartis 2007; \$124,314 (Principal Investigator).
- “Sutent Budget Impact Model and Dossier.” Source: Pfizer 2006; \$80,711 (Principal Investigator).
- “Interface for Sutent Budget Impact Model.” Source: Pfizer 2006; \$29,383 (Principal Investigator).
- “White Paper on Access to Drugs in the Medicare Part D era.” Source: Pfizer 2006; \$18,000 (Principal Investigator).
- “Treatment Patterns, Costs, and Outcomes of Chemotherapy in Prostate and Lung Cancers.” Source: Sanofi-Aventis 2006; \$488,464 (Principal Investigator).
- “Use and Outcomes of Novel Chemotherapeutic Agents in Colorectal Cancer” Source: Sanofi-Aventis 2006; \$650,514 (Principal Investigator).
- “Pharmacy Dispensing Cost Analysis.” Source: Maryland Department of Health and Mental Hygiene (DHMH) 2006; \$24,395 (Principal Investigator).
- “Pharmaceutical Health Policy Seminar Series.” Source: Pfizer 2006; \$50,000 (Principal Investigator).
- “Cost-effectiveness Analysis of Sutent versus Interferon- α as First-line Treatment for Metastatic Renal Cell Carcinoma.” Source: Pfizer 2006; \$60,000 (Principal Investigator).
- “Cost Per Successfully Treated Patient (CPSTP) Estimates for Medicaid Patients.” Source: Pfizer 2006; \$45,578 (Principal Investigator).
- “Formulary Tier Placement for Commonly Prescribed Drugs: Benchmarking and Creation of an Accessibility Index.” Source: Pfizer 2005; \$40,000 (Principal Investigator).
- “Specialty Injectables Benchmarking Study Part 2.” Source: BlueCross BlueShield Association (BCBSA) 2004-2005; \$140,090 (Principal Investigator).
- “Center Effects Influence on Anemia and Mortality.” Source: **NIH/NIDDK (R21DK064126)** 2004; \$62,766=subcontract amount (Co-Investigator; Principal Investigator = Jeffrey C. Fink, MD).
- “Baltimore Partnership Program to Reduce Cardiovascular Disparities.” Source: **NIH/NHLBI (5U01HL079151)** 2004; \$6,000,000 (Co-Investigator; Principal Investigator = Elijah T. Saunders, MD).
- “Hypertension Telemanagement in African Americans.” Source: **NIH/NHLBI (R01HL078579)** 2004; \$2,376,489 (Co-Investigator; Principal Investigator = Joseph Finkelstein, MD).
- “Starting Dose and Persistence of Geodon® Among Medicaid Patients.” Source: Pfizer 2004; \$240,850 (Principal Investigator).
- “Evaluation of an Early Educational Program to Increase Live Kidney Donations.” Source: **HRSA R39OT03408** 2004; \$372,706 (Co-Investigator; Principal Investigator = Stephen T. Bartlett, MD).
- “Schizophrenia/Bipolar Outcomes Research Compendium.” Source: Pfizer 2004; \$55,000 (Principal Investigator).
- “Antifungal Outcomes Research Compendium.” Source: Pfizer 2004; \$45,205 (Principal Investigator).
- “Injectables Expenditure Variations/Benchmarking Study.” Source: BlueCross BlueShield Association (BCBSA) 2003; \$68,000 (Principal Investigator).
- “University of Maryland Center for Health Disparities Research, Training, and Outreach” Source: **NIH (P60MD000532)** 2003; \$4,282,056 (Shared Resources Core Director; Principal Investigator = Donald Wilson, MD).
- “Evaluation of MedBank Demonstration Project.” Source: MedBank of Maryland, Inc. 2003; \$50,000 (Principal Investigator).

- “MRSA Outcomes Research Compendium.” Source: Pfizer 2003; \$45,205 (Co-Principal Investigator; Principal Investigator = Françoise G. Pradel, PhD).
- “Overactive Bladder and urge urinary incontinence Outcomes Research Compendium.” Source: Pfizer 2003; \$45,205 (Principal Investigator).
- “Switching and Discontinuation of SSRI Therapy.” Source: Pfizer 2003; \$139,570 (Principal Investigator).
- “Determinants of Acceptability for Migraine Therapy.” Source: Pfizer 2002; \$50,000 (Principal Investigator).
- “Migraine Budget Impact Model Interface.” Source: Pfizer 2002; \$40,000 (Principal Investigator).
- “White Paper on the Value of Specialty Certification in Pharmacy.” Source: APhA/Board of Pharmaceutical Specialties 2002; \$29,497 (Investigator; Principal Investigator = Françoise G. Pradel, PhD).
- “Combination Therapy Supplement to Eplerenone CEA Grant.” Source: Pharmacia 2002; \$39,704 (Principal Investigator).
- “Migraine Treatment Outcomes Compendium.” Source: Pfizer 2002; \$40,000 (Principal Investigator).
- “Compilation of SOURCE Document.” Source: Pharmacia 2002; \$20,384 (Co-Principal Investigator; Principal Investigator = Françoise G. Pradel, PhD).
- “Variations in the Cost of Cardiovascular events by Country.” Source: Pharmacia 2001; \$28,306 (Principal Investigator).
- “Economic Impact of Uncontrolled Hypertension among chronic arthritis patients: Implications for African Americans.” Source: Pharmacia 2001; \$135,368 (Principal Investigator).
- “White Paper on Direct-To-Consumer Advertising.” Source: Kaiser Family Foundation 2000; \$22,930 (Co-Principal Investigator; Principal Investigator = Francis B. Palumbo, PhD, JD).
- “Annotated Bibliography for Treatment of Congestive Heart Failure (CHF).” Source: USP 2000; \$66,700 (Principal Investigator).
- “Eplerenone CEA.” Source: Searle 2000; \$347,300. (Principal Investigator).
- “Living Donation & Laparoscopic Nephrectomy.” Source: Roche Laboratories 2000; \$130,000 (Co-Principal Investigator; Principal Investigator = Stephen T. Bartlett, MD).
- “Impact of Pipeline Drugs on Future Pharmacy Costs.” Source: HIAA/BCBSA 2000; \$50,012 (Principal Investigator).
- “Prescription Costs for Medicare Beneficiaries: What We Know and What We Need to Know.” Source: DHHS, Assistant Secretary for Policy and Evaluation. Contract No. SA-00-0064 2000; \$24,598 (Co-Investigator; Principal Investigator = Bruce Stuart, PhD).
- “Adult Medicaid Patients’ Dental Visits in EDs.” Source: AHCPR (1 R01 HS10129-01) 1999; \$139,853 (Co-Investigator; Principal Investigator = Len Cohen, DDS).
- “Alpha 1-Antitrypsin Deficiency Cost of Illness Model.” Source: Alpha One Foundation 1998; \$32,956 (Principal Investigator).
- “Cost of IVIG Therapy for PIDDs by Site of Care.” Source: Immune Deficiency Foundation 1998; \$16,100 (Principal Investigator).
- “An Economic Analysis of Alternative Treatment Regimens for Acromegaly.” Source: Novartis Pharmaceutical Corp. 1998; \$27,000 (Co-Investigator; Principal Investigator = Bruce Stuart, PhD).
- “ZEBRA and EORTC Economic Evaluation.” Source: Zeneca Pharmaceuticals 1998; \$15,000 (Principal Investigator).
- “Abciximab Outcomes/Cost Analysis.” Source: School of Pharmacy DRIF Award 1998; \$9,865 (Principal Investigator).
- “Utilization and Cost of IVIG Therapy for PIDDs.” Source: Immune Deficiency Foundation 1998; \$16,675 (Principal Investigator).
- “Econometric Model of Annual Expenditures for Cancer.” Source: School of Medicine DRIF Award 1998; \$15,000 (Co-Investigator; Principal Investigator = Sandra Brooks, MD).

- “Pharmacoconomic Analysis of CAP Program.” Source: Pharmacia & Upjohn (In conjunction with BCBS of MD, BCBS of the National Capital Area, MAMSI, and NYLCare) 1997; \$41,254 (Principal Investigator).
- “Evaluation of Emergency Medical Systems (EMS) Triage of Elderly Trauma Patients.” Source: UMAB Geriatrics and Gerontology Education and Research (GGEAR) Program 1997; \$25,000 (Co-Principal Investigator; Principal Investigator = Jane Scott, ScD).
- “Pharmaceutical Research Monitoring Project.” Source: Merck, Novartis, Pfizer, Pharmacia- Upjohn, and Wyeth-Ayerst 1997; \$25,000/firm = \$125,000 (Principal Investigator on two; Co- Investigator on three).
- “Update of Pharmacoconomic Guidelines/Principle List.” Source: Health Outcomes Work Group at PhRMA 1997; \$14,500 (Principal Investigator).
- “Unrestricted educational grant for development of economic models.” Source: Wyeth-Ayerst Research 1996; \$15,000 (Principal Investigator).
- “Cost-Benefit Analysis of the Community Health Worker Initiative.” Source: UMAB Geriatrics and Gerontology Education and Research (GGEAR) Program 1996; \$19,499 (Principal Investigator).
- “Pharmaceutical Care Outcomes in a Well-Elderly and Frail-Elderly Continuing Care Retirement Community Population Using Multiple Medications.” Source: UMAB Geriatrics and Gerontology Education and Research (GGEAR) Program 1996; \$18,886 (Co-Principal Investigator; Principal Investigator = Maddie Feinberg, PharmD).
- “Medicaid Drug Rebates, Pharmaceutical Prices and Unintended Consequences of Health Policy Reform.” Source: Duke University Center for Aging Studies/The Glaxo Award in Long Term Care Research (Doctoral Dissertation Grant) 1992; \$2,000.

Funded Grants as Mentor

- “Budget Impact of Antidiabetic Formulary Changes” Source: **AHRQ (1F32HS024857-01)** 11/01/16-10/31/17; (Postdoctoral mentee = Anna Hung, PharmD).
- “Prioritizing Quality Improvement for the Treatment of Psychiatric Disturbances Following Traumatic Brain Injury” Source: **AHRQ (K01HS024560)** 03/01/16-2/28/21; (Faculty mentee = Jennifer S. Albrecht).
- “Enhancing Clinical Guideline Development via Patient and Stakeholder Engagement” Source: **AHRQ (K08HS024159)** 07/01/15-6/30/20; (Faculty mentee = Melissa J. Armstrong).
- “Impact of Medicare Contracting Reform on Colon Cancer Treatment, Survival, and Costs” Source: **AHRQ (R36HS022387-01A1)** 04/01/14-3/31/15; (Predoctoral mentee = Joseph Vandigo).
- “Value of Information: The Contribution of the PSA Screening Test to Prostate Cancer Diagnosis” Predoctoral Fellowship in Health Outcomes. Source: Pharmaceutical Research and Manufacturers of America Foundation 06/01/12-05/31/13; (Predoctoral mentee = Emily Reese).
- “Discharges against Medical Advice among Cardiovascular Disease Patients” Source: **NIH (1K12RR023250-01)** 07/01/06-06/30/11; (Principal Investigator = Alan Shuldiner, MD; Faculty mentee = Ebere Onukwugha, PhD).
- “Assessing Anticoagulation Therapy Management Services” Source: **AHRQ (5F32HS016275-01)** 02/01/06-6/30/07; (Postdoctoral mentee = Danielle Chauncey, PharmD).
- “The Application of the Probabilistic Reduction Approach to Health Econometric Model Specification and Testing.” Postdoctoral Fellowship in Health Outcomes. Source: Pharmaceutical Research and Manufacturers of America Foundation 07/01/05-06/30/06; (Postdoctoral mentee = Ebere Akobundu, PhD).

Funded Fellowship Contracts

- “CORE Research Fellowship.” Sources: Merck Sharp and Dohme, Inc; \$210,692 (Principal Investigator). **Funded for 2 years 20016-2018.**

- “Pharmacoconomics/Formulary Management Postdoctoral Fellowship between the University of Maryland School of Pharmacy and the Baltimore Veterans Administration.” Sources: Elan, Sanofi-Aventis; \$75,000 (Principal Investigator). **Funded for 4 years 2005-2009.**
- “Pharmacoconomics/Formulary Management Postdoctoral Fellowship between the University of Maryland School of Pharmacy and CareFirst BlueCross BlueShield (BCBS).” Sources: Pharmacia, Pfizer, Takeda; \$75,000 (Principal Investigator). **Funded for 7 consecutive years 2001-2008.**
- “Pharmacoconomics/Pain Management Postdoctoral Fellowship.” Source: Alpharma; \$75,000 (Principal Investigator). **Funded for 1 year 2007-2008.**
- “Pharmacoconomics and Medicaid Formulary Management Postdoctoral Fellowship between the University of Maryland School of Pharmacy and various Medicaid Plans.” Sources: Novartis, Pharmacia, Pfizer; \$75,000 (Co-Principal Investigator; Principal Investigator = Fadia T. Shaya, PhD, MPH). **Funded for 5 consecutive years 2002-2007.**
- “Pharmacoconomics/Formulary Management Postdoctoral Fellowship between the University of Maryland School of Pharmacy and the Mid Atlantic Medical Services, Inc. (MAMSI).” Sources: Pharmacia, Eli Lilly; Pfizer; \$65,000 (Principal Investigator). **Funded for 5 consecutive years 2000-2005.**
- “Pharmacoconomics/ Formulary Management Postdoctoral Fellowship between the University of Maryland School of Pharmacy and the Maryland Health Services Cost Review Commission (HSCRC).” Source: MedBank of Maryland, Inc.; \$55,000 (Principal Investigator). **Funded for 1 year 2004.**
- “Pfizer Predoctoral Fellowship in Pharmacoconomics and Outcomes Research.” Source: Pfizer; \$43,200 (Principal Investigator). **Funded for 1 year 2003.**

PUBLICATIONS

- Mattingly TJ 2nd, Slezko JF, Onukwugha E, Perfetto EM, Kottilil S, Mullins CD. Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. *Pharmacoconomics* 2019; forthcoming.
- Albrecht JS, Wickwire EM, Mullins CD, Rao V. Patterns of Psychotropic Medication Use among Individuals with Traumatic Brain Injury. *Journal of Neurotrauma* 2019; forthcoming.
- Mattingly TJ 2nd, Slezko JF, Perfetto EM, Kottilil S, Mullins CD. What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism. *The Patient – Patient-Centered Outcomes Research* 2019 Dec;12(6):631-638.
- O'Hara NN, Degani Y, Marvel D, Wells D, Mullins CD, Wegener S, Frey K, Joseph T, Hurst J, Castillo R, O'Toole RV; PREVENT CLOT Stakeholder Committee. Which orthopaedic trauma patients are likely to refuse to participate in a clinical trial? A latent class analysis. *BMJ Open* 2019;9(10):e032631.
- Bekelman JE, Lu H, Pugh S, Baker K, Berg CD, de Gonzalez AB, Braunstein LZ, Bosch W, Chauhan C, Ellenberg S, Fang LC, Freedman GM, Hahn EA, Haffty BG, Khan AJ, Jimenez RB, Kesslering C, Ky B, Lee C, Lu HM, Mishra MV, Mullins CD, Mutter RW, Nagda S, Pankuch M, Powell SN, Prior FW, Schupak K, Taghian AG, Wilkinson JB, MacDonald SM, Cahlon O; RadComp (Radiotherapy Comparative Effectiveness Consortium). Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol. *BMJ Open* 2019;9(10):e025556.
- Hung A, Lugo A, Mullins CD. Modeling the Budgetary Impact of Payer Utilization Management Strategies: An Adapted Framework Based on Lessons Learned. *Journal of Managed Care & Specialty Pharmacy* 2019;25(8):922-926.
- Hung A, Slezko JF, Lugo A, Shaya F, Haines ST, Mullins CD. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study. *Journal of Managed Care & Specialty Pharmacy* 2019;25(8):913-921.

- Mullins CD. Evolving Use of Real-World Evidence for Devices: Good for Patients, Good for Policy Makers. *Value in Health* 2019;22(7):751-753.
- Armstrong MJ, Gronseth GS, Day GS, Rheaume C, Alliance S, Mullins CD. Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing. *Alzheimer Disease & Associated Disorders* 2019; 33(3):246-53.
- Slejko JF, Mattingly TJ 2nd, Mullins CD, Perfetto EM, dosReis S. Future of Patients in Healthcare Evaluation: The Patient-Informed Reference Case. *Value in Health* 2019; 22(5):545-548.
- Drummond MF, Mullins CD. "Back to the Future" With Value in Health. *Value Health* 2019;22(5):503-504.
- Mattingly II TJ, Mullins CD, Melendez DR, Boyden K, Eddington ND. A Systematic Review of Entrepreneurship in Pharmacy Practice and Education. *American Journal of Pharmaceutical Education* 2019; 83(3): Article 7233.
- Natafgi N, Tafari AT, Chauhan C, Bekelman JE, Mullins CD. Patients' early engagement in research proposal development (PEER-PD): patients guiding the proposal writing. *Journal of Comparative Effectiveness Research* 2019; 8(6):441-453.
- Levy JF, Khairnar R, Louie AV, Showalter TN, Mullins CD, Mishra MV. Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy. *Practical Radiation Oncology* 2019; 9(2):e172-e179.
- Hung A, Mullins CD, Slejko JF, Haines ST, Shaya F, Lugo A. Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools. *Journal of Managed Care & Specialty Pharmacy* 2019; 25(3):342-349.
- Schanberg LE, Mullins CD. If patients are the true north, patient-centeredness should guide research. *Nature Reviews Rheumatology* 2019;15(1):5-6.
- Newhouse R, Janney M, Gilbert A, Agley J, Bakoyannis G, Ferren M, Mullins CD, Johantgen M, Schwindt R, Thoelle K. Study Protocol Testing Toolkit versus Usual Care for Implementation of Screening, Brief Intervention, Referral to Treatment in Hospitals: A Phased Cluster Randomized Approach. *Addiction Science & Clinical Practice* 2018; 13(1):28.
- Onukwugha E, Jayasekera J, Gardner J, Malik S, Mullins CD, Hussain A, Ciezki JP, Reddy CA, Seal B, Valderrama A, Kwok Y. An Approach to Identify Delivery of Palliative Radiation Therapy Using Health Care Claims Data: A Proof-of-Concept Application of a Visual Analytics Tool. *JCO Clinical Cancer Informatics* 2018; 2:1-12.
- Sieluk J, Levy J, Sandhaus RA, Silverman H, Holm KE, Mullins CD. Costs of Medical Care Among Augmentation Therapy Users and Non-Users with Alpha-1 Antitrypsin Deficiency in the United States. *Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation (JCOPDF)* 2018;6(1):6-16.
- Albrecht JS, Rao V, Perfetto EM, Mullins CD. Safety of Antidepressant Classes Used Following Traumatic Brain Injury Among Medicare Beneficiaries: A Retrospective Cohort Study. *Drugs & Aging* 2018; 35(8):763–772.
- Onukwugha E, Albarmawi H, Sun K, Mullins CD, Aly A, Hussain A. Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis. *Urologic Oncology* 2018; 36(7):340.e23-340.e31.
- Mullins CD, Wingate LT, Edwards HA, Tofade T, Wutoh A. Transitioning from learning healthcare systems to learning health care communities. *Journal of Comparative Effectiveness Research* 2018; 7(6):603-614.
- Perfetto EM, Harris J, Mullins CD, dosReis S. Emerging Good Practices for Transforming Value Assessment: Patients' Voices, Patients' Values. *Value in Health* 2018; 21(4):386-393.
- Armstrong MJ, Mullins CD, Gronseth GS, Gagliardi AR. Impact of patient involvement on clinical practice guideline development: a parallel group study. *Implementation Science* 2018; 13(1):55.
- Ross MM, Arria AM, Brown JP, Mullins CD, Schiffman J, Simoni-Wastila L, dosReis S. College students' perceived benefit-to-risk tradeoffs for nonmedical use of prescription stimulants: Implications for intervention designs. *Addictive Behaviors* 2018; 79:45-51.

- Hussain A, Yong C, Tkaczuk KHR, Qian Y, Arellano J, Mullins CD, Onukwugha E. Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer. *PLoS One* 2018; 13(3):e0193661.
- Ng X, dosReis S, Beardsley R, Magder L, Mullins CD, Petri M. Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids. *Lupus* 2018; 27(3):475–483.
- Oehrlein EM, Graff JS, Perfetto EM, Mullins CD, Dubois RW, Anyanwu C, Onukwugha E. Peer-Reviewed Journal Editors' Views on Real-World Evidence. *International Journal of Technology Assessment in Health Care* 2018; 34(1):111-119.
- Mallya UG, Boklage SH, Koren A, Delea TE, Mullins CD. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease. *Pharmacoconomics* 2018; 36(1):115-126.
- Hong YD, Goto D, Mullins CD. Querying stakeholders to inform comparative effectiveness research. *Journal of Comparative Effectiveness Research* 2017; 6(3):265–273.
- Chirikov VV, Shaya FT, Onukwugha E, Mullins CD, dosReis S, Howell CD. Tree-based Claims Algorithm for Measuring Pretreatment Quality of Care in Medicare Disabled Hepatitis C Patients. *Medical Care* 2017; 55(12):e104-e112.
- Albrecht JS, O'Hara LM, Moser KA, Mullins CD, Rao V. Perception of Barriers to the Diagnosis and Receipt of Treatment for Neuropsychiatric Disturbances After Traumatic Brain Injury. *Archives of Physical Medicine and Rehabilitation* 2017; 98(12):2548-2552.
- Mattingly TJ 2nd, Slepko JF, Mullins CD. Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What? *Annals of Pharmacotherapy* 2017; 51(11):961-969.
- Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M; joint ISPE-ISPOR Special Task Force on Real World Evidence in Health Care Decision Making. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. *Value in Health* 2017; 20(8):1009-1022. Co-published in *Pharmacoepidemiology and Drug Safety* 2017; 26(9):1033-1039.
- Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R, Wang SV, Watkins J, Mullins CD. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. *Value in Health* 2017; 20(8):1003-1008. Co-published in *Pharmacoepidemiology and Drug Safety* 2017; 26(9):1018-1032.
- Haac BE, O'Hara NN, Mullins CD, Stein DM, Manson TT, Johal H, Castillo R, O'Toole RV, Slobogean GP. Patient preferences for venous thromboembolism prophylaxis after injury: a discrete choice experiment. *BMJ Open* 2017; 7(8):e016676.
- Huang J, Lipman PD, Mullins CD. Bridging the divide: building infrastructure to support community-academic partnerships and improve capacity to conduct patient-centered outcomes research. *Translational Behavioral Medicine* 2017; 7:773–782.
- Goto D, Shih YT, Lecomte P, Olson M, Udeze C, Park Y, Mullins CD. Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. *Pharmacoconomics* 2017; 35(7):685-695.
- Sofolahan-Oladeinde Y, Newhouse RP, Lavallee DC, Huang JC, Mullins CD. Early assessment of the 10-step patient engagement framework for patient-centered outcomes research studies: the first three steps. *Family Practice* 2017; 34(3):272-277.
- Albrecht JS, Mullins DC, Smith GS, Rao V. Psychotropic Medication Use among Medicare Beneficiaries Following Traumatic Brain Injury. *American Journal of Geriatric Psychiatry* 2017; 25(4):415-424.
- Onukwugha E, Kwok Y, Ciezki JP, Yong C, Plaisant C, Reddy CA, Mullins CD, Seal B, Valderrama A, Hussain A. Skeletal-related events and mortality among men diagnosed with

- advanced prostate cancer: The impact of alternative measures of radiation to the bone. *PLoS One* 2017; 12(4):e0175956.
- Aly A, Yoder D, Pradel F, Mullins CD. Payers' Views on the Heterogeneity of Treatment Effect in Oncology. *The American Journal of Pharmacy Benefits* 2017; 9(3):75-81.
- Wieland LS, Berman BM, Altman DG, Barth J, Bouter LM, D'Adamo CR, Linde K, Moher D, Mullins CD, Treweek S, Tunis S, van der Windt DA, Zwarenstein M, Witt C. Rating of Included Trials on the Efficacy-Effectiveness Spectrum: development of a new tool for systematic reviews. *Journal of Clinical Epidemiology* 2017; 84:95-104.
- Onukwugha E, Yong C, Naslund M, Woods C, Mullins CD, Seal B, Hussain A. Specialist visits and initiation of cancer-directed treatment among a large cohort of men diagnosed with prostate cancer. *Urologic Oncology* 2017; 35(4):150.e17-150.e23.
- He T, Mullins CD. Age-related racial disparities in prostate cancer patients: A systematic review. *Ethnicity & Health* 2017; 22(2):184-195.
- Armstrong MJ, Mullins CD, Gronseth GS, Gagliardi AR. Recommendations for patient engagement in guideline development panels: A qualitative focus group study of guideline-naïve patients. *PLoS One* 2017; 12(3):e0174329.
- Armstrong MJ, Mullins CD. Value Assessment at the Point of Care: Incorporating Patient Values throughout Care Delivery and a Draft Taxonomy of Patient Values. *Value in Health* 2017; 20(2):292-295.
- Holt CL, Graham-Phillips AL, Mullins CD, Slade JL, Savoy A., Carter R. Health ministry and activities in African American faith-based organizations: A qualitative examination of facilitators, barriers, and use of technology. *Journal of Health Care for the Poor and Underserved* 2017; 28(1):378-388.
- Armstrong MJ, Rueda JD, Gronseth GS, Mullins CD. Framework for enhancing clinical practice guidelines through continuous patient engagement. *Health Expectations* 2017; 20(1):3-10.
- Mullins CD, Ernst FR, Krukas MR, Solomkin J, Eckmann C, Shelbaya A, Quintana A, Reisman A. Value of Propensity Score Matching for Equalizing Comparator Groups in Observational Database Studies: A Case Study in Anti-infectives. *Clinical Therapeutics* 2016; 38(12):2676-2681.
- Hussain A, Aly A, Daniel Mullins C, Qian Y, Arellano J, Onukwugha E. Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis. *Cancer Medicine* 2016; 5(11):3300-3309.
- Mattingly TJ 2nd, Mullins CD, Onukwugha E. Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter? *PharmacoEconomics* 2016; 34(10):1067-70.
- Dunlop WC, Mullins CD, Pirk O, Goeree R, Postma MJ, Enstone A, Heron L. BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles. *PharmacoEconomics* 2016; 34(10):1051-65.
- Luce BR, Connor JT, Broglio KR, Mullins CD, Ishak KJ, Saunders E, Davis BR; RE-ADAPT (REsearch in ADaptive methods for Pragmatic Trials) Investigators. Using Bayesian Adaptive Trial Designs for Comparative Effectiveness Research: A Virtual Trial Execution. *Annals of Internal Medicine* 2016; 165(6):431-8.
- Rattinger GB, Fauth EB, Behrens S, Sanders C, Schwartz S, Norton MC, Corcoran C, Mullins CD, Lyketsos CG, Tschanz JT. Closer caregiver and care-recipient relationships predict lower informal costs of dementia care: The Cache County Dementia Progression Study. *Alzheimer's & Dementia* 2016; 12(8):917-24.
- Roghmann MC, Lydecker A, Mody L, Mullins CD, Onukwugha E. Strategies to Prevent MRSA Transmission in Community-Based Nursing Homes: A Cost Analysis. *Infection Control & Hospital Epidemiology* 2016; 37(8):962-6.
- Solomkin J, Mullins CD, Quintana A, Eckmann C, Shelbaya A, Ernst FR, Krukas MR, Reisman A. Evaluation of Tigecycline Efficacy and Post-Discharge Outcomes in a Clinical Practice Population with Complicated Intra-Abdominal Infection: A Propensity Score-Matched Analysis. *Surgical Infections* 2016; 17(4):402-11.

- Lopez JM, Katic BJ, Fitz-Randolph M, Jackson RA, Chow W, Mullins CD. Understanding preferences for type 2 diabetes mellitus self-management support through a patient-centered approach: a 2-phase mixed-methods study. *BMC Endocrine Disorders* 2016; 16(1):41.
- Woldemichael A, Onukwuga E, Seal B, Hanna N, Mullins CD. Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients. *Journal of Managed Care & Specialty Pharmacy* 2016; 22(6):628-39.
- Bikov KA, Mullins CD, Hung A, Seal B, Onukwuga E, Hanna N. Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients with Metastatic Colon Cancer. *The Oncologist* 2016; 21(6):676-83.
- Armstrong MJ, Shulman LM, Vandigo J, Mullins CD. Patient engagement and shared decision-making: What do they look like in neurology practice? *Neurology Clinical Practice* 2016; 6(2):190-197.
- Chen J, Mullins CD, Novak P, Thomas SB. Personalized Strategies to Activate and Empower Patients in Health Care and Reduce Health Disparities. *Health Education & Behavior* 2016; 43(1):25-34.
- Vandigo J, Oloyede E, Aly A, Laird AL, Cooke CE, Mullins CD. Continuous patient engagement in cardiovascular disease clinical comparative effectiveness research. *Expert Review of Pharmacoeconomics & Outcomes Research* 2016; 16(2):193-8.
- Onukwuga E, McRae J, Kravetz A, Varga S, Khairnar R, Mullins CD. Cost-of-Illness Studies: An Updated Review of Current Methods. *Pharmacoeconomics* 2016; 34(1):43-58.
- Rycroft CE, Hirst M, Dunlop WC, Pirk O, Mullins D, Akehurst R. The Suitability of End Point Designs for Health Technology Assessment in Chronic Pain Studies. *Value in Health* 2015; 18(8):987-93.
- Chirikov VV, Mullins CD, Hanna N, Breunig IM, Seal B, Shaya FT. Multispecialist Care and Mortality in Hepatocellular Carcinoma. *American Journal of Clinical Oncology* 2015; 38(6):557-63.
- Sofolahan-Olaideinde Y, Mullins CD, Baquet CR. Using community-based participatory research in patient-centered outcomes research to address health disparities in under-represented communities. *Journal of Comparative Effectiveness Research* 2015; 4(5):515-23.
- Chirikov VV, Shaya FT, Mullins CD, dosReis S, Onukwuga E, Howell CD. Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C. *Expert Review of Gastroenterology & Hepatology* 2015; 9(11):1447-1462.
- Wiener ES, Mullins CD, Pincus KJ. A framework for pharmacist-assisted medication adherence in hard-to-reach patients. *Research in Social and Administrative Pharmacy* 2015; 11(5):595-601.
- Aly A, Onukwuga E, Woods C, Mullins CD, Kwok Y, Qian Y, Arellano J, Balakumaran A, Hussain A. Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods. *BMC Medical Research Methodology* 2015; 15:65.
- Rattinger GB, Schwartz S, Mullins CD, Corcoran C, Zuckerman IH, Sanders C, Norton MC, Fauth EB, Leoutsakos JM, Lyketsos CG, Tschanz JT. Dementia severity and the longitudinal costs of informal care in the Cache County population. *Alzheimer's & Dementia* 2015; 11(8): 946-54.
- Bikov KA, Mullins CD, Seal B, Onukwuga E, Hanna N. Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare. *Medical Care* 2015; 53(8):e58-64.
- Aly A, Mullins CD, Hussain A. Understanding heterogeneity of treatment effect in prostate cancer. *Current Opinion in Oncology* 2015; 27(3):209-16.
- Ung BL, Mullins CD. The Affordable Care Act, health care reform, prescription drug formularies and utilization management tools. *Research in Social and Administrative Pharmacy* 2015; 11(3):459-67.
- Chew TW, Gau CS, Wen YW, Shen LJ, Mullins CD, Hsiao FY. Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study. *BMC Cancer* 2015; 15:298.

- Perman JA, Mullins CD, Newhouse R. Population Health and the Patient in *The Transformation of Academic Health Centers*, 2015; Chapter 19:195-202, San Diego, CA: Academic Press (an imprint of Elsevier).
- Mullins CD, Onwudiwe NC, Branco de Araújo GT, Chen W, Xuan J, Tichopád A, Hu S. Guidance Document: Global Pharmacoeconomic Model Adaption Strategies. *Value in Health Regional Issues* 2014; 5:7-13.
- Miller MF, Mullins CD, Onukwugha E, Golant M, Buzaglo JS. Discriminatory power of a 25-item distress screening tool: a cross-sectional survey of 251 cancer survivors. *Quality of Life Research* 2014; 23(10):2855-63.
- Bae YH, Mullins CD. Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs? *Journal of Managed Care Pharmacy & Specialty Pharmacy* 2014; 20(11):1086-92.
- Onukwugha E, Osteen P, Jayasekera J, Mullins CD, Mair CA, Hussain A. Racial Disparities in Urologist Visits Among Elderly Men with Prostate Cancer: A Cohort Analysis of Patient-Related and County of Residence-Related Factors. *Cancer* 2014; 120(21):3385-92.
- Trivedi D, Landsman-Blumberg P, Darkow T, Smith D, McMorrow D, Mullins CD. Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment. *Journal of Managed Care Pharmacy & Specialty Pharmacy* 2014; 20(10):1006-15.
- Shih YCT, Daniel CM, Drummond M. The Role of Economic Evaluation in Meeting IOM's Recommendations on Delivering High-Quality Cancer Care. *Value in Health* 2014; 17(5):479-500.
- Onwudiwe NC, Kwok Y, Onukwugha E, Sorkin JD, Zuckerman IH, Shaya FT, Mullins CD. Cardiovascular event-free survival after adjuvant radiation therapy in breast cancer patients stratified by cardiovascular risk. *Cancer Medicine* 2014; 3(5):1342-52.
- Zheng Z, Onukwugha E, Hanna N, Bikov K, Seal B, Mullins CD. Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients. *Advances in Therapy* 2014; 31(7):724-34.
- Yong C, Onukwugha E, Mullins CD, Seal B, Hussain A. The Use of Health Services among Elderly Patients with Stage IV Prostate Cancer in the Initial Period following Diagnosis. *Journal of Geriatric Oncology* 2014; 5(3):290-8.
- Onukwugha E, Yong C, Mullins CD, Seal B, McNally D, Hussain A. Skeletal-Related Events and Mortality Among Older Men with Advanced Prostate Cancer. *Journal of Geriatric Oncology* 2014; 5(3):281-9.
- Mullins CD, Vandigo J, Zheng Z, Wicks P. Patient-centeredness in the design of clinical trials. *Value in Health* 2014; 17(4):471-5.
- Lavallee DC, Wicks P, Alfonso Cristancho R, Mullins CD. Stakeholder Engagement in Patient-Centered Outcomes Research: High-Touch or High-Tech? *Expert Review of Pharmacoeconomics & Outcomes Research* 2014; 14(3):335-44.
- Zheng Z, Hanna N, Onukwugha E, Bikov KA, Mullins CD. Hospital Center Effect for Laparoscopic Colectomy Among Elderly Stage I-III Colon Cancer Patients. *Annals of Surgery* 2014; 259(5):924-9.
- Yong C, Onukwugha E, Mullins CD. Clinical and Economic Burden of Bone Metastasis and Skeletal-Related Events in Prostate Cancer. *Current Opinion in Oncology* 2014; 26(3):274-83.
- Johnston SS, Udall M, Alvir J, McMorrow D, Fowler R, Mullins D. Characteristics, Treatment, and Health Care Expenditures of Medicare Supplemental-Insured Patients with Painful Diabetic Peripheral Neuropathy, Post-Herpetic Neuralgia, or Fibromyalgia. *Pain Medicine* 2014; 15(4):562-76.
- Johnson W, Shaya FT, Winston R, Laird A, Mullins CD, Chirikov VV, Saunders E. Diabetes Control Through an Educational Intervention. *Ethnicity & Disease* 2014; 24(2):182-8.
- Berger ML, Martin BC, Husereau D, Worley K, Allen JD, Yang W, Quon NC, Mullins CD, Kahler KH, Crown W. A Questionnaire to Assess the Relevance and Credibility of Observational Studies to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. *Value in Health* 2014; 17(2):143-56.

- Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B, Hussain A. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. *Pharmacoeconomics* 2014; 32(2):173-91.
- Zheng Z, Hanna H, Onukwugha E, Reese ES, Seal B, Mullins CD. Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. *Cancer Medicine* 2014; 3(1):124-33.
- Onukwugha E, Yong C, Hussain A, Seal B, Mullins CD. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer. *BMC Medical Research Methodology* 2014; 14:1.
- Shaya FT, Breunig IM, Seal B, Mullins CD, Chirikov VV, Hanna N. Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare. *PharmacoEconomics* 2014; 32(1):63-74.
- Buzaglo J, Gayer C, Mallick R, Charap E, Ferris A, Golant M, Langer C, Morris A, Mullins CD, Cella D. Understanding the experience of living with non-small-cell lung cancer (NSCLC): a qualitative study. *The Journal of Community and Supportive Oncology* 2014; 12(1):6-12.
- Reese ES, Onukwugha E, Hanna N, Seal BS, Mullins CD. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. *Cancer Medicine* 2013; 2(6):907-15.
- Mullins CD, Yang HK, Onukwugha E, Eisenberg DF, Myers DE, Huang DB, Lodise TP. Rehospitalizations and Direct Medical Costs for cSSSI: Linezolid Versus Vancomycin. *The American Journal of Pharmacy Benefits* 2013; 5(6):258-67.
- Mitikiri ND, Reese ES, Hussain A, Onukwugha E, Pritchard D, Dubois R, Mullins CD. The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a model. *Journal of Comparative Effectiveness Research* 2013; 2(6):605-18.
- Sonnad SS, Mullins CD, Whicher D, Goldsack JC, Mohr PE, Tunis SR. Recommendations for the Design of Phase 3 Pharmaceutical Trials that are more Informative for Patients, Clinicians, and Payers. *Contemporary Clinical Trials* 2013; 36(2):356-61.
- Connor JT, Luce BR, Broglio KR, Ishak KJ, Mullins CD, Vanness DJ, Fleurence R, Saunders E, Davis BR. Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. *Clinical Trials* 2013; 10(5):807-27.
- Ratner J, Mullins CD, Buesching DP, Cantrell RA. Pragmatic Clinical Trials: US Payers' Views on Their Value. *The American Journal of Managed Care* 2013; 19(5):e158-e165.
- Kauffman KS, dosReis S, Ross M, Barnet B, Onukwugha E, Mullins CD. Engaging hard-to-reach patients in patient-centered outcomes research. *Journal of Comparative Effectiveness Research* 2013; 2(3):313-24.
- Mullins CD, Jain R, Weir MR, Franey CS, Shih YC, Pradel FG, Bikov K, Bartlett ST. Benefits Improvement and Protection Act's Impact on Transplantation Rates Among Elderly Medicare Beneficiaries with End-Stage Renal Disease. *Transplantation* 2013; 15;95(3):463-9.
- Shaya FT, Chirikov VV, Mullins CD, Shematek J, Howard D, Foster C, Saunders E. Social Networks Help Control Hypertension. *The Journal of Clinical Hypertension* 2013; 15(1):34-40.
- Hung A, Mullins CD. Relative Effectiveness and Safety of Chemotherapy in Elderly and Nonelderly Patients with Stage III Colon Cancer: A Systematic review. *The Oncologist* 2013; 18(1):54-63.
- Johnston SS, Juday T, Seekins D, Hebden T, Fulcher N, Farr AM, Chu BC, Mullins CD. Patterns and Correlates of Linkage to Appropriate HIV Care After HIV Diagnosis in the US Medicaid Population. *Sexually Transmitted Diseases* 2013; 40(1):18-25.
- Willke RJ, Zheng Z, Subedi P, Althin R, Mullins CD. From concepts, theory and evidence of heterogeneity of treatment effects to methodological approaches: a primer. *BMC Medical Research Methodology* 2012; 12:185.
- Rattinger GB, Mullins CD, Zuckerman IH, Onukwugha E, Walker LD, Gundlapalli A, Samore M, DeLisle S. A Sustainable Strategy to Prevent Misuse of Antibiotics for Acute Respiratory Infections. *PLoS ONE* 2012; 7(12):e51147.

- Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W, Frank ES, Lipscomb J, Raymond SA, Spencer M, Tunis S. Recommendations for Incorporating Patient-Reported Outcomes into Clinical Comparative Effectiveness Research in Adult Oncology. *Journal of Clinical Oncology* 2012; 30(34):4249-55.
- Onukwuga E, Saunders E, Mullins CD, Pradel FG, Zuckerman M, Loh FE, Weir MR. A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting. *BMJ Open* 2012; 2(4):e000902.
- Hanna N, Bikov KA, McNally D, Onwudiwe NC, Dalal M, Mullins CD. Impact of Venous Thromboembolism on Mortality of Elderly Medicare Patients with Stage III Colon Cancer. *The Oncologist* 2012; 17(9):1191-7.
- Mullins CD, Dunn JD. Applying Oncology Formulary and Benefit Design Innovations to the Management of Multiple Myeloma in the Managed Care Setting. *Journal of Managed Care Pharmacy* 2012; 18(8-a):S13-9.
- Manabe YC, Hermans SM, Lamorde M, Castelnuovo B, Mullins CD, Kuznik A. Rifampicin for Continuation Phase Tuberculosis Treatment in Uganda: A Cost-Effectiveness analysis. *PLoS ONE* 2012; 7(6):e39187.
- Hsiao FY, Mullins CD, Huang WF. Economic Evaluation of Thiazolidinediones as Add-on Therapy for Treatment of Type 2 Diabetic Patients in the Taiwanese National Health Insurance System. *Journal of Food and Drug Analysis* 2012; 20(2):1-7.
- Mullins CD, Hsiao FY, Onukwuga E, Pandya NB, Hanna N. Comparative and Cost-Effectiveness of Oxaliplatin-based or Irinotecan-based Regimens Compared with 5-Fluorouracil/Leucovorin Alone Among US Elderly Stage IV Colon Cancer Patients. *Cancer* 2012; 118(12):3173-81.
- Reese E, Mullins CD, Beitelhees AL, Onukwuga E. Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel. *Pharmacotherapy* 2012; 32(4):323-32.
- Rapp T, Andrieu S, Molinier L, Grand A, Cantet C, Mullins CD, Vellas B. Exploring the Relationship between Alzheimer's Disease Severity and Longitudinal Costs *Value in Health* 2012; 15(3):412-9.
- Mullins CD, Abdulhalim AM, Lavallee DC. Continuous Patient Engagement in Comparative Effectiveness Research. *JAMA* 2012; 307(15): 1587-8.
- Mullins CD, Montgomery R, Abernethy AP, Hussain A, Pearson SD, Tunis S. Recommendations for Clinical Trials of Off-Label Drugs Used to Treat Advanced-Stage Cancer. *Journal of Clinical Oncology* 2012; 30(6):661-6.
- Mullins CD, Shaya FT, Blatt L, Saunders E. A Qualitative Evaluation of a Citywide Community Health Partnership Program. *Journal of the National Medical Association* 2012; 104(1 and 2):53-60.
- Hanna NN, Onukwuga E, Choti MA, Davidoff AJ, Zuckerman IH, Hsu VD, Mullins CD. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using Surveillance, Epidemiology and End Results (SEER)-Medicare data. *Colorectal Disease* 2012; 14(1):48-55.
- Jain R, Mullins CD, Lee H, Wong W. Use of rosiglitazone and pioglitazone immediately after the cardiovascular risk warnings. *Research in Social and Administrative Pharmacy* 2012; 8(1):47-59.
- Willke RJ, Mullins CD. "Ten Commandments" for Conducting Comparative Effectiveness Research Using "Real-World Data." *Journal of Managed Care Pharmacy* 2011; 17(9 Suppl A):S10-5.
- Sanchez RJ, Mardekian J, Cziraky MJ, Mullins CD. Developing a Collaborative Study Protocol for Combining Payer-Specific Data and Clinical Trials for CER. *Journal of Managed Care Pharmacy* 2011; 17(9 Suppl A):S34-7.
- Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW. Relationship between Cardiovascular Outcomes and Proton Pump Inhibitor Use in Patients Receiving Dual

- Antiplatelet Therapy after Acute Coronary Syndrome. *Pharmacoepidemiology and Drug Safety* 2011; 20(10):1043-9.
- Mullins CD, Ratner J, Ball DE. How Do US Payers React to and Use Pharmacoeconomic Information? *International Journal of the Economics of Business* 2011; 18(2):317-30.
- Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD. The Value of Atorvastatin over the Product Life Cycle in the United States. *Clinical Therapeutics*. 2011; 33(10):1433-43.
- Ezeugwu CO, Laird A, Mullins CD, Saluja DS, Winston RA. Lessons Learned from Community-Based Minority Health Care Serving System Participation in an NIH Clinical Trial. *Journal of the National Medical Association* 2011; 103(9 and 10):839-44.
- Hsiao FY, Mullins CD, Onukwugha E, Pandya N, Hanna N. Comparative Effectiveness of Different Chemotherapeutic Regimens on Survival of People Aged 66 and Older with Stage III Colon Cancer: A "Real World" Analysis Using Surveillance, Epidemiology, and End Results-Medicare Data. *Journal of the American Geriatrics Society* 2011; 59(9):1717-23.
- Johnson W, Shaya F, Khanna N, Warrington VO, Rose VA, Yan X, Bailey-Weaver B, Mullins CD, Saunders E. The Baltimore Partnership to Educate and Achieve Control of Hypertension (The BPTEACH Trial): A Randomized Trial of the Effect of Education on Improving Blood Pressure Control in a Largely African-American Population. *The Journal of Clinical Hypertension* 2011; 13(8):563-70.
- Wang J, Liu X, Mullins CD. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. *Current Medical Research and Opinion* 2011; 27(7):1303-13.
- Grabner M, Onukwugha E, Jain R, Mullins CD. Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. Co-published as *The American Journal of Managed Care*. 2011; 17(5 Spec No.):e151-e159; *Journal of Oncology Practice* 7(3 Suppl):e16s-24s.
- Onukwugha E, Mullins CD, Hsu VD, Seal B, Hussain A. Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer. *Urology* 2011; 77(5):1088-95.
- Schneider M, Zuckerman IH, Onukwugha E, Pandya N, Seal B, Gardner J, Mullins CD. Chemotherapy Treatment and Survival in Older Women with Estrogen Receptor-Negative Metastatic Breast Cancer: A Population-Based Analysis. *Journal of the American Geriatrics Society* 2011; 59(4):637-46.
- Onukwugha E, Mullins CD, Loh FE, Saunders E, Shaya FT, Weir MR. Readmissions after unauthorized discharges in the cardiovascular setting. *Medical Care* 2011; 49(2):215-24.
- Bradley-Baker LR, Mullins CD, Baquet CR. Pharmacists' Assessment of Facets of Health Literacy in Pharmacy Practice Settings. *Journal of Pharmacy Technology* 2011; 27:55-62.
- Onwudiwe NC, Mullins CD, Winston RA, Shaya FT, Pradel FG, Laird A, Saunders E. Barriers to Self-Management of Diabetes: A Qualitative Study among Low-Income Minority Diabetics. *Ethnicity & Disease* 2011; 21(1):27-32.
- Mullins CD, Hsu VD, Cooke CE, Shelbaya A, Wallace AE, Perencevich EN. Rehospitalization Rates among Linezolid vs. Vancomycin Users. *The American Journal of Pharmacy Benefits* 2011; 3(2):e1-e13.
- Mullins CD, Onukwugha E, Cooke JL, Hussain A, Baquet CR. The Potential Impact of Comparative Effectiveness Research on the Health of Minority Populations. *Health Affairs* 2010; 29(11):2098-104.
- Valluri S, Zito JM, Safer DJ, Zuckerman IH, Mullins CD, Korelitz JJ. Impact of the 2004 Food and Drug Administration Pediatric Suicidality Warning on Antidepressant and Psychotherapy Treatment for New-Onset Depression. *Medical Care* 2010; 48(11):947-54.
- Valluri S, Lyons B, Mullins CD. Impact of Food and Drug Administration (FDA) Paediatric Antidepressant Warnings on Stock Prices of Pharmaceutical Manufacturers. *Journal of Pharmaceutical Health Services Research* 2010; 61-7.
- Mullins CD, Whicher D, Reese E, Tunis S. Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled Trials. *PharmacoEconomics* 2010; 28(10):969-76.

- Bollinger ME, Morphew T, Mullins CD. The Breathmobile Program: A Good Investment for Underserved Children with Asthma. *Annals of Allergy, Asthma & Immunology* 2010; 105(4):274-281.
- Rattinger GB, Mullins CD, Zuckerman IH, Onukwugha E, DeLisle S. Clinic Visits and Prescribing Patterns Among Veterans Affairs Maryland Health Care System Dementia Patients. *The Journal of Nutrition Health and Aging* 2010; 14(8):677-83.
- Onukwugha E, Saunders E, Mullins CD, Pradel FG, Zuckerman M, Weir MR. Reasons for discharges against medical advice: a qualitative study. *Quality and Safety in Health Care* 2010; 19(5):420-4.
- Mullins CD, Onukwugha E, Bikov K, Seal B, Hussain A. Health Disparities in Staging of SEER-Medicare Prostate Cancer Patients in the United States. *Urology* 2010; 76(3):566-72.
- Wang J, Mullins CD, Chang CF, Gourley DR, Shih YT, Cushman WC, Dagogo-Jack S, White-Means SI. Comparisons of changes over time in per capita health expenditures across racial and ethnic groups. *International Journal of Public Policy* 2010; 6(3/4):172-89.
- Obeidat NA, Pradel FG, Zuckerman IH, Trovato JA, Palumbo FB, DeLisle S, Mullins CD. Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer. *The American Journal of Managed Care* 2010; 16(7):515-522.
- Margolis JM, Cao Z, Onukwugha E, Sanchez RJ, Alvir J, Joshi AV, Mullins CD. Healthcare Utilization and Cost Effects of Prior Authorization for Pregabalin in Commercial Health Plans. *The American Journal of Managed Care* 2010; 16(6):447-56.
- Wang J, Mullins CD, Brown LM, Shih YT, Dagogo-Jack S, Hong SH, Cushman WC. Disparity Implications of Medicare Eligibility Criteria for Medication Therapy Management Services. *Health Services Research* 2010; 45(4):1061-82.
- Barnet B, Rapp T, DeVoe M, Mullins CD. Cost-effectiveness of a Motivational Intervention to Reduce Rapid Repeated Childbearing in High-Risk Adolescent Mothers: A Rebirth of Economic and Policy Considerations. *Archives of Pediatrics & Adolescent Medicine* 2010; 164(4):370-6.
- Mullins CD, Montgomery R, Tunis S. Uncertainty in Assessing Value of Oncology Treatments. *The Oncologist* 2010; 15(suppl 1):58-64.
- Bridges JF, Onukwugha E, Mullins CD. Healthcare Rationing by Proxy: Cost-Effectiveness Analysis and the Misuse of the \$50,000 Threshold in the US. *Pharmacoconomics* 2010; 28(3):175-84.
- Hsiao FY, Mullins CD. The Association between Thiazolidinediones and Hospitalisation for Fracture in Type 2 Diabetic Patients: A Taiwanese Population-Based Nested Case-Control Study. *Diabetologia* 2010; 53(3):489-96.
- Belletti D, Zacker C, Mullins CD. Perspectives on electronic medical records adoption: electronic medical records (EMR) in outcomes research. *Patient Related Outcome Measures* 2010; 1:29-37.
- Palumbo FB, Simoni-Wastila L, Lavallee DC, Blatt L, Mullins CD. Access to Pharmaceuticals in the Post-Medicare Part D Era. *Journal of Pharmaceutical Health Services Research* 2010; 1:9-14.
- Mullins CD, Seal B, Seoane-Vazquez E, Sankaranarayanan J, Asche CV, Jayadevappa R, Lee WC, Romanus DK, Wang J, Hay JW, Smeeding J. Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report – Part IV. *Value in Health* 2010; 13(1):18-24.
- Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L. Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report – Part I. *Value in Health* 2010; 13(1):3-7.
- Mullins CD, Seal B, Blatt L. The Financial Implications of New Episodes of MDD for Treatment Resistant Versus Stable Depressed Individuals. *Journal of Managed Care Medicine* 2009; 12(4):5-12.

- Obeidat NA, Pradel FG, Zuckerman IZ, DeLisle S, Mullins CD. Outcomes of Irinotecan-Based Chemotherapy Regimens in Elderly Medicare Patients with Metastatic Colorectal Cancer. *The American Journal of Geriatric Pharmacotherapy* 2009; 7(6):343-54.
- Davidoff AJ, Rapp T, Onukwugha E, Zuckerman IH, Hanna N, Pandya N, Mullins CD. Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients: The Role of the Medical Oncologist Evaluation. *Medical Care* 2009; 47(12):1229-36.
- Margolis JM, Johnston SS, Chu BC, Onukwugha E, Hvidsten K, Alvir J, Rossi JG, Mullins CD. Effects of a Medicaid Prior Authorization Policy for Pregabalin. *The American Journal of Managed Care* 2009; 15(10):e95-102.
- Zuckerman IH, Rapp T, Onukwugha E, Davidoff A, Choti MA, Gardner J, Seal B, Mullins CD. Effect of Age on Survival Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer. *Journal of the American Geriatrics Society* 2009; 57(8):1403-10.
- Pradel FG, Suwannaprom P, Mullins CD, Sadler J, Bartlett ST. Haemodialysis Patients' Readiness to Pursue Live Donor Kidney Transplantation. *Nephrology Dialysis Transplantation* 2009; 24(4):1298-305.
- Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The Total Economic Burden of Overactive Bladder in the United States: A Disease-Specific Approach. *The American Journal of Managed Care* 2009; 15(4 suppl):S90-7.
- Mullins CD. New Perspectives on Overactive Bladder and Its Treatment: Introduction. *The American Journal of Managed Care* 2009; 15(4 suppl):S88-9.
- Blak BT, Mullins CD, Shaya FT, Simoni-Wastila L, Cooke CE, Weir MR. Prescribing Trends and Drug Budget Impact of the ARBS in the UK. *Value in Health* 2009; 12(2):302-8.
- Mullins CD, Rattinger GB, Kuznik A, Koren MJ. Cost-Effectiveness of Intensive Atorvastatin Treatment in High-Risk Patients Compared with Usual Care in a Postgeneric Statin Market: Economic Analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study. *Clinical Therapeutics* 2008; 30:2204-16.
- Pradel FG, Suwannaprom P, Mullins CD, Sadler J, Bartlett ST. Short-term impact of an educational program promoting live donor kidney transplantation in dialysis centers. *Progress in Transplantation* 2008; 18(4):263-72.
- Pradel FG, Jain R, Mullins CD, Vassalotti JA, Bartlett ST. A Survey of Nephrologists' Views on Preemptive Transplantation. *Clinical Journal of the American Society of Nephrology* 2008; 3(6):1837-45.
- Wang J, Mullins CD, Zuckerman IH, Walker GD, Suda KJ, Yang Y, White-Means SI. Medical Expenditure Panel Survey: A Valuable Database for Studying Racial and Ethnic Disparities in Prescription Drug Use. *Research in Social and Administrative Pharmacy* 2008; 4(3):206-17.
- Balkrishnan R, Joish VN, Yang T, Jayawant SS, Mullins CD. The Economic Burden Associated with SSRI Treatment Failure in a Managed Care Population. *Journal of Medical Economics* 2008; 11(4):601-10.
- Mullins CD, Subedi PR, Turk F. Impact of Patient Sample on Costs of Events in Pharmacoeconomic Models. *Expert Review of Pharmacoeconomics & Outcomes Research* 2008; 8(5): 463-9.
- Rattinger GB, Jain R, Ju J, Mullins CD. Principles of Economics Crucial to Pharmacy Students' Understanding of the Prescription Drug Market. *American Journal of Pharmaceutical Education* 2008; 72(3):61.
- Asche C, McAdam-Marx C, Seal B, Crookston B, Mullins CD. Treatment Costs Associated with Community-Acquired Pneumonia by Community Level of Antimicrobial Resistance. *Journal of Antimicrobial Chemotherapy* 2008; 61(5):1162-8.
- Holtorf AP, Watkins JB, Mullins CD, Brixner D. Incorporating Observational Data into the Formulary Decision-Making Process – Summary of a Roundtable Discussion. *Journal of Managed Care Pharmacy* 2008; 14(3):302-8.
- Onukwugha E, Mullins CD, DeLisle S. Using Cost-Effectiveness Analysis to Sharpen Formulary Decision-Making: The Example of Tiotropium at the Veterans Affairs Health Care System. *Value in Health* 2008; 11(5):980-8.

- Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD. Risk of Discontinuation of Atypical Antipsychotic Agents in the Treatment of Schizophrenia. *Schizophrenia Research* 2008; 98(1-3):8-15.
- Palumbo FB, Mullins CD, Slagle AF, Rizer J. Policy Implications of Drug Importation. *Clinical Therapeutics* 2007; 29(12):2758-67.
- Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices – Budget Impact Analysis. *Value in Health* 2007; 10(5):336-47.
- Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report. *Value in Health* 2007; 10(5):326-35.
- Mullins CD, Subedi PR, Healey PJ, Sanchez RJ. Economic Analysis of Triptan Therapy for Acute Migraine: A Medicaid Perspective. *Pharmacotherapy* 2007; 27(8):1092-1101.
- Wang J, Zuckerman IH, Miller NA, Shaya FT, Noel JM, Mullins CD. Utilizing New Prescription Drugs: Disparities among Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites. *Health Services Research* 2007; 42(4):1499-519.
- Mullins CD, Palumbo FB, Saba M. Formulary Tier Placement for Commonly Prescribed Branded Drugs: Benchmarking and Creation of a Preferred Placement Index. *The American Journal of Managed Care* 2007; 13(6, Part 2):377-84.
- Onukwugha E, Mullins CD. Racial Disparities in Hospital Discharge Disposition among Stroke Patients in Maryland. *Medical Decision Making* 2007; 27(3):233-42.
- Wang J, Mullins CD, Mamdani M, Rublee DA, Shaya FT. New Diagnosis of Hypertension Among Celecoxib and Nonselective NSAID Users: A Population-Based Cohort Study. *The Annals of Pharmacotherapy* 2007; 41(6):937-43.
- Shaya FT, Samant N, Pradel F, Mullins CD, Scharf SM, Britt J. Health-related quality of life as a potential predictor in chronic obstructive lung disease patients. *Expert Review of Pharmacoeconomics & Outcomes Research* 2007; 7(2):129-35.
- Fink JC, Hsu VD, Zhan M, Walker LD, Mullins CD, Jones-Burton C, Langenberg P, Seliger SL. Center Effects in Anemia Management of Dialysis Patients. *Journal of the American Society of Nephrology* 2007; 18(2):646-53.
- Wang J, Noel JM, Zuckerman IH, Miller NA, Shaya FT, Mullins CD. Disparities in Access to Essential New Prescription Drugs between Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites. *Medical Care Research and Review* 2006; 63(6):742-63.
- Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-Illness Studies: A Review of Current Methods. *Pharmacoeconomics* 2006; 24(9):869-90.
- Mullins CD, Pradel FG, Meng F, Blatt L, Bartlett ST. Relative Costs of Transplantation versus Dialysis. *Journal of the Association for Academic Minority Physicians* 2006; 17:36-43.
- Mullins CD, Lavallee DC, Pradel FG, DeVries AR, Caputo N. Health Plans' Strategies for Managing Outpatient Specialty Pharmaceuticals. *Health Affairs* 2006; 25(5):1332-9.
- Mullins CD, Kuznik A, Shaya FT, Obeidat NA, Levine AR, Liu LZ, Wong W. Cost-Effectiveness Analysis of Linezolid Compared with Vancomycin for the Treatment of Nosocomial Pneumonia Caused by Methicillin-Resistant *Staphylococcus aureus*. *Clinical Therapeutics* 2006; 28(8):1184-98.
- Chauncey D, Mullins CD, Tran BV, McNally D, McEwan RN. Medication access through patient assistance programs. *American Journal of Health-System Pharmacy* 2006; 63(13):1254-9.
- Shaya FT, El Khoury AC, Mullins CD, Du D, Skolasky R, Fatodu H, Garber H, Weir MR. Drug Therapy Persistence and Stroke Recurrence. *The American Journal of Managed Care* 2006; 12(6):313-9.
- Mullins CD, Shaya FT, Zito JM, Obeidat N, Naradzay J, Harrison DJ. Effect of initial ziprasidone dose on treatment persistence in schizophrenia. *Schizophrenia Research* 2006; 83(2-3):277-284.

- Pradel FG, Subedi P, Varghese AA, Mullins CD, Weis KA. Does earlier headache response equate to earlier return to functioning in patients suffering from migraine? *Cephalgia* 2006; 26(4):428-35.
- Mullins CD, Shaya FT, Meng F, Wang J, Bron MS. Comparison of First Refill Rates Among Users of Sertraline, Paroxetine, and Citalopram. *Clinical Therapeutics* 2006; 28(2):297-305.
- Baquet CR, Commiskey P, Mullins CD, Mishra SI. Recruitment and participation in clinical trials: Socio-demographic, rural/urban, and health care access predictors. *Cancer Detection and Prevention* 2006; 30(1):24-33.
- Perfetto EM, Weis KA, Mullins CD, Subedi P, Healey PJ. An Economic Evaluation of Triptan Products for Migraine. *Value in Health* 2005; 8(6):647-55.
- Benner JS, Smith TW, Klingman D, Tierce JC, Mullins CD, Pethick N, O'Donnell JC. Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective. *Value in Health* 2005; 8(6):618-28.
- Mullins CD, Blatt L, Gbarayor CM, Yang HK, Baquet C. Health disparities: A barrier to high-quality care. *American Journal of Health-System Pharmacy* 2005; 62(18):1873-82.
- Mullins CD, DeVries AR, Hsu VD, Meng F, Palumbo FB. Variability and Growth in Spending For Outpatient Specialty Pharmaceuticals. *Health Affairs* 2005; 24(4):1117-27.
- Mullins CD, Subak LL. New Perspectives on Overactive Bladder: Quality of Life Impact, Medication Persistence, and Treatment Costs. *The American Journal of Managed Care* 2005 11(4 suppl):S101-2.
- Shaya FT, Klaskala W, Mullins CD. Review of cost-effectiveness studies of pegylated therapies for hepatitis C. *Expert Review of Pharmacoeconomics & Outcomes Research* 2005; 5(3):339-51.
- Shaya FT, Shin JY, Mullins CD, El Khoury AC, Garber H. Risk of Heart Failure with the Use of Thiazolidinediones within a Medicaid Population. *Pharmacy and Therapeutics* 2005; 30(5): 273-4, 279-81.
- Mullins CD, Weis KA, Perfetto EM, Subedi PR, Healey PJ. Triptans for Migraine Therapy: A Comparison Based on Number Needed to Treat and Doses Needed to Treat. *Journal of Managed Care Pharmacy* 2005; 11(5):394-402.
- Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, Switching, and Discontinuation Rates Among Patients Receiving Sertraline, Paroxetine, and Citalopram. *Pharmacotherapy* 2005; 25(5):660-7.
- Mauskopf JA, Earnshaw S, Mullins CD. Budget impact analysis: review of the state of the art. *Expert Review of Pharmacoeconomics & Outcomes Research* 2005; 5(1):65-79.
- Shaya FT, Shin JY, Mullins CD, Fatodu HO, Gu A, Saunders E. Medicaid Managed Care: Disparities in the Use of Thiazolidinediones Compared with Metformin. *Journal of the National Medical Association* 2005; 97(4):493-7.
- Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD. Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects: An Observational Study of a Medicaid Population. *Archives of Internal Medicine* 2005; 165(2):181-6.
- Mullins CD, Thomas SK, Cooke J. The Impact of Pharmacogenomics on the Cost-Effectiveness Ratio in *Principles of Pharmacoeconomics*, 3rd edition 2005; Chapter 10:237-58, Cincinnati, OH: Harvey Whitney Books Company.
- Mullins CD, Snyder SE, Wang J, Cooke JL, Baquet C. Economic Disparities in Treatment Costs among Ambulatory Medicaid Cancer Patients. *Journal of the National Medical Association* 2004; 96(12):1565-74.
- Zuckerman IH, Menis M, McNally DL, Layne BA, Mullins CD. Intervention for Decreasing Excessive Acetaminophen Use In Pennsylvania Medicaid Recipients. *American Journal of Health-System Pharmacy* 2004; 61(22):2410-4.
- Mullins CD, Cohen LA, Magder LS, Manski RJ. Medicaid Coverage and Utilization of Adult Dental Services. *Journal of Health Care for the Poor and Underserved* 2004; 15(4):672-87.

- Pradel FG, Palumbo FB, Flowers L, Mullins CD, Haines ST, Roffman DS. White Paper: Value of Specialty Certification in Pharmacy. *Journal of the American Pharmacists Association* 2004; 44(5):612-20.
- Mullins CD, Sikirica M, Seneviratne V, Ahn J, Akhras KS. Comparisons of Hypertension-Related Costs from Multinational Clinical Studies. *Pharmacoeconomics* 2004; 22(15):1001-1014.
- Shaya FT, Blume S, Mullins CD. Prescription Drug Spending Tends For The Privately Insured in Maryland, 2000-2001. *Health Affairs* 2004; 23(5):226-32.
- Zuckerman IH, Weiss SR, McNally D, Layne B, Mullins CD, Wang J. Impact of an Educational Intervention for Secondary Prevention of Myocardial Infarction on Medicaid Drug Use and Cost. *The American Journal of Managed Care* 2004; 10(7):493-500.
- Mullins CD, Cooke JL, Wang J, Shaya FT, Hsu VD, Brooks S. Disparities in Prevalence Rates for Lung, Colorectal, Breast, and Prostate Cancers in Medicaid. *Journal of the National Medical Association* 2004; 96(6):809-16.
- Grant WC, Yoder DM, Mullins CD. Threshold denial rates in prior authorization prescription programs. *Expert Review of Pharmacoeconomics & Outcomes Research* 2004; 4(2):165-9.
- Mullins CD, Wang J, Cooke JL, Blatt L, Baquet CR. Longitudinal versus Cross-Sectional Methodology for Estimating the Economic Burden of Breast Cancer: A Pilot Study. *Pharmacoeconomics* 2004; 22(5):285-91.
- Mullins CD, Shaya FT, Flowers LR, Saunders E, Johnson W, Wong W. Health Care Cost of Analgesic Use in Hypertensive Patients. *Clinical Therapeutics* 2004; 26(2):285-93.
- Cohen LA, Magder LS, Manski RJ, Mullins CD. Hospital Admissions Associated with Nontraumatic Dental Emergencies in a Medicaid Population. *American Journal of Emergency Medicine* 2003; 21(7):540-4.
- Mullins CD, Wang J, Stoller JK. Major Components of the Direct Medical Costs of Alpha 1-Antitrypsin Deficiency. *Chest* 2003; 124(3):826-31.
- Mullins CD, Flowers LR. Evaluating Economic Outcomes Literature in *Pharmacoeconomics and Outcomes: Applications for Patient Care, 2nd edition* 2003; Chapter 14:246-65, Kansas City, MO: American College of Clinical Pharmacy.
- Cohen LA, Manski RJ, Magder LS, Mullins CD. A Medicaid Population's Use of Physicians' Offices for Dental Problems. *American Journal of Public Health* 2003; 93(8):1297-1301.
- Pradel FG, Mullins CD, Bartlett ST. Exploring Donors' and Recipients' Attitudes About Living Donor Kidney Transplantation. *Progress in Transplantation* 2003; 13(3):203-10.
- Mullins CD, Thomas SK, Pradel FG, Bartlett ST. The Economic Impact of Laparoscopic Living-Donor Nephrectomy on Kidney Transplantation. *Transplantation* 2003; 75(9):1505-12.
- Mullins CD. Response to Torrance et al. [Osteoarthritis and Cartilage 2002; 10:518-27]. Letter to the editor. *Osteoarthritis and Cartilage* 2003; 11:377-8.
- Pradel FG, Limcangco MR, Mullins CD, Bartlett ST. Patients' Attitudes About Living Donor Transplantation and Living Donor Nephrectomy. *American Journal of Kidney Diseases* 2003 41(4):849-58.
- Mullins CD, Ndiritu EM, Yoder DM, Shaya FT, Taylor TA. Impact of the Fourth Hurdle on the International Pharmaceutical Industry. *Expert Review of Pharmacoeconomics & Outcomes Research* 2003; 3(2):169-177.
- Mullins CD, Ohsfeldt RL. Modeling the Annual Costs of Postmenopausal Prevention Therapy: Raloxifene, Alendronate, or Estrogen-Progestin Therapy. *Journal of Managed Care Pharmacy* 2003; 9(2):150-8.
- Merchant S, Mullins CD, Shih YT. Factors Associated with Hospitalization Costs for Patients with Community-Acquired Pneumonia *Clinical Therapeutics* 2003; 25(2):593-610.
- Palumbo FB, Mullins CD. The Development of Direct-to-Consumer Prescription Drug Advertising Regulation. *Food and Drug Law Journal* 2002; 57(3):423-43.
- Thomas SK, Brooks SE, Mullins CD, Baquet CR, Merchant S. Use of ICD-9 Coding as a Proxy for Stage of Disease in Lung Cancer. *Pharmacoepidemiology and Drug Safety* 2002; 11(8):709-13.

- Brooks SE, Ahn J, Mullins CD, Baquet CR. Resources and Use of the Intensive Care Unit in Patients Who Undergo Surgery for Ovarian Carcinoma. *Cancer* 2002; 95(7):1457-62.
- Shaya FT, Mullins CD, Wong W. Incidence versus prevalence modeling in pharmacoeconomics. *Expert Review of Pharmacoeconomics & Outcomes Research* 2002; 2(5):435-42.
- Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation Rates of Topical Glaucoma Medications in a Managed Care Population. *The American Journal of Managed Care* 2002; 8(10 suppl):S271-7.
- Mullins CD, Philbeck TE, Schroeder WJ, Thomas SK. Cost Effectiveness of Kinetic Therapy in Preventing Nosocomial Lower Respiratory Tract Infections in Patients Suffering from Trauma. *Managed Care Interface* 2002; 15(8):35-40.
- Mullins CD, Blak BT, Akhras KS. Comparing Cost-Effectiveness Analyses of Anti-Hypertensive Drug Therapy for Decision Making: Mission Impossible? *Value in Health* 2002; 5(4):359-71.
- Cohen LA, Manski RJ, Magder LS, Mullins CD. Dental visits to hospital emergency departments by adults receiving Medicaid: Assessing their use. *Journal of the American Dental Association* 2002; 133:715-24.
- Baquet CR, Hammond C, Comiskey P, Brooks S, Mullins CD. Health Disparities Research - A Model for Conducting Research on Cancer Disparities: Characterization and Reduction. *Journal of the Association for Academic Minority Physicians* 2002; 13(2):33-40.
- Mullins CD, Blatt L, Wang J. Societal implications of the pharmacoeconomics of Alpha 1-antitrypsin deficiency. *Expert Review of Pharmacoeconomics & Outcomes Research* 2002; 2(3):243-9.
- Brooks SE, Mullins CD, Guo C, Chen TT, Gardner JF, Baquet CR. Resource Utilization for Patients Undergoing Hysterectomy with or without Lymph Node Dissection for Endometrial Cancer. *Gynecologic Oncology* 2002; 85(2):242-9.
- Mullins CD, Wang J. Pharmacy Benefit Management: Enhancing the Applicability of Pharmacoeconomics for Optimal Decision Making. *Pharmacoeconomics* 2002; 20(1):9-21.
- Mullins CD, Lyons BM, Ahn J. Pharmaceutical Market Impact of the Early 1990's Health Care Debate. *Journal of Research in Pharmaceutical Economics* 2001; 11(2):1-22.
- Mullins CD. The Economics of Lipid Management. *Managed Care* 2001; 10(11 Suppl):S17-18.
- Perfetto EM, Mullins CD, Subedi P, Li-McLeod J. Selection of Clinical, Patient-Reported, and Economic End Points in Acute Exacerbation of Chronic Bronchitis. *Clinical Therapeutics* 2001; 23(10):1747-72.
- Mullins CD, Wang J, Palumbo FB, Stuart B. The Impact of Pipeline Drugs on Drug Spending Growth. *Health Affairs* 2001; 20(5):210-215.
- Brooks SE, Ahn J, Mullins CD, Baquet CR, D'Andrea A. Health Care Cost and Utilization Project Analysis of Comorbid Illness and Complications for Patients Undergoing Hysterectomy for Endometrial Cancer. *Cancer* 2001; 92(4):950-8.
- Mullins CD, Huang X, Merchant S, Stoller JK. The Direct Medical Costs of Alpha 1-Antitrypsin Deficiency. *Chest* 2001; 119(3):745-52.
- Mullins CD, Thomas SK, Roffman DS. Pharmaceutical Restrictions: Possible Effect on Patient/Physician Buy-in of Disease Management Programs. *Disease Management & Health Outcomes* 2001; 9(2):69-74.
- Kulsomboon V, Palumbo FB, Mullins CD. Criteria to Request Pharmacoeconomic Data and Data Sources for Hospital Formulary Decisions. *Drug Information Journal* 2001; 35(1):231-240.
- Mullins CD, Merchant S. Guidelines and Information Requirements in *Introduction to Applied Pharmacoeconomics* 2001; Chapter 11:229-261, New York: McGraw-Hill.
- Mullins CD, Whitelaw G, Cooke JL, Beck EJ. Indirect Cost of HIV Infection in England. *Clinical Therapeutics* 2000; 22(11):1333-45.
- Brooks SE, Chen TT, Ghosh A, Mullins CD, Gardner JF, Baquet CR. Cervical Cancer Outcomes Analysis: Impact of Age, Race and Comorbid Illness on Hospitalizations for Invasive Carcinoma of the Cervix. *Gynecologic Oncology* 2000; 79(1):107-15.

- Reed SO, Mullins CD, Magder LS. Cost Effectiveness of Abciximab During Routine Medical Practice. *Pharmacoconomics* 2000; 18(3):265-74.
- Luchette FA, Barrie PS, Oswanski MF, Spain DA, Mullins CD, Palumbo F, Pasquale MD. Practice Management Guidelines for Prophylactic Antibiotic Use in Tube Thoracostomy for Traumatic Hemopneumothorax. *The Journal of Trauma* 2000; 48(4):753-7.
- Luchette FA, Borzotta AP, Croce MA, O'Neill PA, Whittmann DH, Mullins CD, Palumbo F, Pasquale MD. Practice Management Guidelines for Prophylactic Antibiotic Use in Penetrating Abdominal Trauma. *The Journal of Trauma* 2000; 48(3):508-18.
- Mullins CD. An Overview of Cancer Economics. *The American Journal of Managed Care* 1999; 5(6 suppl):S371-S376.
- Amin SP, Mullins CD, Duncan BS and Blandford L. Direct health care costs for treatment of diabetes mellitus and hypertension in an IPA-group-model HMO. *American Journal of Health-System Pharmacy* 1999; 56(15):1515-20.
- Weidle P, Bradley L, Gallina J, Mullins CD, Thorn D, and Siegel LP. Pharmaceutical Care Intervention Documentation Program and Related Cost Savings at a University Hospital. *Hospital Pharmacy* 1999; 34(1):43-52.
- Mullins CD and Ogilvie SD. Emerging Standardization in Pharmacoconomics. *Clinical Therapeutics* 1998; 20(6):1194-1202.
- Reed SD, Mullins CD, Roffman DS and Mays DA. Difficulties in applying clinical trial information to the practice setting: Case of a high-cost drug. *American Journal of Health-System Pharmacy* 1998; 55(22):2409-14.
- Mullins CD and Palumbo FB. Maintaining Public Assistance Data in the Managed Care Era. *SGIM (Society of General Internal Medicine) Forum* 1998; 21(3):5,10.
- Mullins CD, Cooke CE, and Cooke JL. Applications of Pharmacoconomics for Managed Care Pharmacy. *Journal of Managed Care Pharmacy* 1997; 3(6):720-726.
- Grabowski HG and Mullins CD. Pharmacy Benefit Management, Cost-Effectiveness Analysis, and Drug Formulary Decisions. *Social Science & Medicine* 1997; 45(4):535-544.
- Mullins CD, Morris LS, Perfetto EM and Ogilvie SD. Pharmacoconomics of NSAIDs: Beyond Bleeds. *Journal of Managed Care Pharmacy* 1997; 3(4):425-430.
- Palumbo FB and Mullins CD. Quality-of-care data from managed care organizations. Letter to the editor. *New England Journal of Medicine* 1997; 336(6):443-444.
- Mullins CD. Price and Welfare Implications of a Medicare Pharmaceutical Rebate. *New York Health Sciences Journal* 1996; 1(4):243-255.
- Mullins CD. Most-Favored-Customer Protection and Medicaid Rebates under OBRA 1990. *Journal of Research in Pharmaceutical Economics* 1996; 7(3):49-63.
- Mullins CD and Weisman ES. A Simplified Approach to Teaching Markov Models. *American Journal of Pharmaceutical Education* Spring 1996; 60(1):42-7.
- Mullins CD, Baldwin R and Perfetto EM. What Are Outcomes? *Journal of the American Pharmaceutical Association* January 1996; NS36(1):39-49.
- Mullins CD. Toward an Understanding of Pharmaceutical Pricing Strategies Through the Use of Simple Game Theoretic Models. *Journal of Research in Pharmaceutical Economics* 1995; 6(3):1-14. (Reprinted in Smith, MC, ed. *Studies in Pharmaceutical Economics*. New York: Pharmaceutical Products Press, 1996.)
- Hartzema AG and Mullins CD. *Pharmaceutical Chartbook*. New York: Pharmaceutical Products Press, 1995.
- Mullins CD. Combining the Principles of Epidemiology and Economics. *American Journal of Pharmaceutical Education* Winter 1994; 58[4]:427-430.
- Mullins CD. Drug Firm-Mail-Order Mergers: Marriages of Convenience? *American Pharmacy* August 1994; NS34(8):38-42.

Reports

- Stuart B, Brandt N, Briesacher B, Fahlman C, Mullins D, Palumbo F, Pizarro J, Stuart L. Issues in Prescription Drug Coverage, Pricing, Utilization, and Spending: What We Know and Need

to Know. *A report for the US Department of Health and Human Services (HHS), Office of the Assistant Secretary for Policy and Evaluation, Office of Health Policy*, February 18, 2000.

Mullins CD, Palumbo F, Stuart B. Projections of Drug Approvals, Patent Expirations, and Generic Entry from 2000 to 2004. *A background report for the US Department of Health and Human Services (HHS) conference on: What is known and what needs to be known about prescription drug costs and pricing practices*. August 8-9, 2000, Georgetown University, Washington, DC.

Book Reviews

- Mullins CD. *Review of Peter J. Neumann's Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers in Value in Health* 2006; 9(2):140.
- Mullins CD. *Review of Robert M. Sloane, et al.'s Introduction to Healthcare Delivery Organizations: Functions and Management, Fourth edition* in *American Journal of Pharmaceutical Education* Spring 2000; 64:106.
- Mullins CD. *Review of Stuart O. Schweitzer's Pharmaceutical Economics and Policy* in *American Journal of Pharmaceutical Education* Spring 1998; 62:104-5.

PRESENTATIONS

- “The PATIENTS Program and our PCOR/CER Experiences from the Field” Pre-Conference Diagnostic Researcher Workshop at the Diagnostic Error in Medicine 12th International Conference, Washington, DC, November 2019.
- “Patient Science and Engagement” Pre-Meeting Workshop Chair at the 10th MDEpiNet Annual Meeting, Silver Spring, MD, October 2019.
- “Session III: Patient Science and Engagement Efforts” Panel Moderator at the 10th MDEpiNet Annual Meeting, Silver Spring, MD, October 2019.
- “The PATIENTS Program and our 10-Step Framework for Continuous Patient Engagement” at the Maryland Board of Pharmacy Annual Continuing Education (CE) Breakfast, Towson, MD, October 2019.
- “Pharmapreneurship™—Disruptive Innovation in Pharmacy” at the American Association of Colleges of Pharmacy (AAP) Annual Meeting, Chicago, IL, July 2019.
- “Funding for Improving Patient and Community Health” at the CASE Annual Conference for Corporate and Foundation Relations Officers, Washington, DC, May 2019.
- “Back to the Future in *Value in Health*” course presented at ISPOR 2019 Conference, New Orleans, LA, May 2019.
- “Budget Impact Analysis I: A 6-Step Approach” short course presented at ISPOR 2019 Conference, New Orleans, LA, May 2019; also at the ISPOR Conferences (2014-2018), the ISPOR European Conferences (2013-2018), ISPOR Latin America Conference (2011, 2013, 2017, and 2019) and the ISPOR Asia Pacific Conferences (2012, 2018).
- “Engaging Community Partners to Transform Learning Healthcare Systems into Learning Health Care Communities” Keynote on Community Based Research at Society of Behavioral Medicine’s 40th Annual Meeting & Scientific Sessions, Washington, DC, March 2019.
- “Re-Imagining Healthcare: Making Learning Health Systems More Community Based” Keynote address at the University of Texas Health Science Center at San Antonio’s Re-Imagining Healthcare: A Lifecourse Approach to Community Based Care Conference, San Antonio, TX, November 2018.
- “Community-Engaged Research: Making Clinical and Translational Research More Meaningful to Patients and Communities” at the University of Maryland Medical Grand Rounds ICTR Lecture Series, Baltimore, MD, September 2018.
- “An Overview of The PATIENTS Program” at the American Association of College of Pharmacy and Research!America, Arlington, VA, September 2018 ; also presented at BCBSA Pharmacy and Medical Policy Committee (PMPC) Meeting, Washington, DC, September 2018; and at

- Baltimore County Association of Senior Citizens Organizations' Educational Forum and Health & Wellness Fair, Randallstown, MD, September 2018.
- “Case Study #3: The RADCOMP Consortium Experience: Patient Engagement in a Large Pragmatic Randomized Clinical Trial” at The University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) Medical Devices - Patient Engagement in Real World Evidence (RWE): Lessons Learned and Best Practices Conference, Baltimore, MD, September 2018.
- “From Community-Based Participatory Research to Community-Based Healing” at the IPFCC’s 8th International Conference on Patient- and Family-Centered Care, Baltimore, MD, May 2018.
- “Real-World Evidence, Digital Health, and the New Landscape for Health Decision Making” ISPOR 2018 Conference Co-Chair, Baltimore, MD, May 2018.
- “Second Plenary Session: Digital Health – Help or Hype?” Moderator at ISPOR 2018, Baltimore, MD, May 2018.
- “Transforming Health Care: Making Learning Health Systems more Community Base” at the Henry Ford Patient Engaged Research Center 2nd Annual Patient Advisor Retreat; Detroit, MI, May 2018.
- “Session III: Morning Synthesis Discussion” panel at the FDA and the Duke-Margolis Center for Health Policy Public Workshop: Evaluating Inclusion and Exclusion Criteria in Clinical Trials; Washington, DC, April 2018.
- “Patient-Centered Discovery” presented as the Coy W. Waller Distinguished Lecture at the University of Mississippi, University, MS, February 2018; also presented at the Howard University School of Pharmacy Dean’s Lectureship series; Washington, DC, February 2018.
- “Capacity Building and Sustainability: An Academic Perspective” presented at the FDA UCSF-CERSI Patient Preference Workshop, Silver Spring, MD, December 2017.
- “Introduction to Designing Authentic and Impactful Patient-Centered Outcomes Research” short course presented at the ISPOR 20th Annual European Congress, Glasgow, Scotland, November 2017.
- “Power Sharing and Collaboration in Community Engaged Research” presented at the Johns Hopkins Nuts & Bolts of Community Engaged Research Workshop, Baltimore, MD, December 2017.
- “Keynote Address” at PCORI Workshop at Indiana University, Indianapolis, IN, October 2017.
- “Medical Editor Panel” Moderator at the ISPOR/ISPE Summit on Real-World Evidence in Health Care Decision Making, Washington, DC, October 2017.
- “Transparency Recommendations” presented at the ISPOR/ISPE Summit on Real-World Evidence in Health Care Decision Making, Washington, DC, October 2017.
- “Budget Impact Models: How Payers Can Build and Validate” presented at AMCP Nexus, Dallas, TX, October 2017.
- “KEYNOTE: From Community-Based Participatory Research to Community-Based Healing;” at the University of Texas Health Science Center at San Antonio’s Community Engagement and Healthcare Improvement Conference, San Antonio, TX, September 2017.
- “Building a Budget Impact Model: Budget Impact Analysis Training”, ISPOR In-Person Training Program, New Brunswick, NJ, September 2017. Also presented in Durham, NC, November 2016.
- “OPENING MASTER CLASS: Patients & Advocacy Integrated into the Ethos of the Pharmaceutical Corporation” at the 6th Annual Strengthening Patient Advocacy Relations Conference, Baltimore, MD, July 2017.
- “Evidence base: community values, engagement, and health disparity” at the National Academy of Medicine’s Care Culture and Decision-Making Innovation Collaborative meeting, Washington, DC, May 2017.
- “Engaging Patients in Research Process” roundtable facilitator at the 2017 American Pharmacists Association (APhA) Annual Meeting, San Francisco, CA, March 2017.

- “ESAS Keynote: Making Community-Based Participatory Research Work in Health Care” presented at the 2017 American Pharmacists Association (APhA) Annual Meeting, San Francisco, CA, March 2017.
- “How the multi-stakeholder movement can lead to a better world of healthcare” presented at the Evidence-Based Guidelines Affecting Policy, Practice and Stakeholders (E-GAPPS III) Conference, New York, NY, March 2017.
- “Engagement in the Community” presented at the 2016 PCORI Annual Meeting: Pre-Conference for Ambassadors and Patient Scholarships, National Harbor, MD, November 2016.
- “Does Conservatism by Registration Authorities in their Requirements for Outcome Measures in Pain Trials Hamper Drug Development in that Area?” issue panel presented at the ISPOR 19th Annual European Congress, Vienna, Austria, October 2016.
- “Metrics and Measurement in Community Engaged Research: How Do We Assess Authenticity?” presented at the Advancing the Science of Community Engaged Research: Innovative and Effective Methods of Stakeholder Engagement in Translational Research, Washington, DC, August 2016.
- “Stakeholder Engagement and Communication” roundtable facilitator at the 2016 American Pharmacists Association (APhA) Annual Meeting, Baltimore, MD, March 2016.
- “Continuous Patient Engagement: How Do We Partner with Patients Throughout the Research Life Cycle?” panel moderator at the ISPOR 20th Annual International Meeting, Philadelphia, PA, May 2015.
- “Real World Evidence – Defining What “Good” Looks Like” panel member at the 2nd Annual Green Park Collaborative-USA Meeting, Baltimore, MD, April 2015.
- “Patient Differences: Biologic and Non-Biologic Factors” presented at the National Minority Quality Forum (NMQF) Conference on *Biodiversity and Health Care Quality: The 21st Century Challenge*, Washington, DC, April 2015.
- “PDUFA V Clinical Outcomes Assessment Development and Implementation: Opportunities and Challenges Public Workshop” Session 4: Strategies Going Forward panel member at the Food and Drug Administration (FDA) Meeting, Silver Spring, MD, April 2015.
- “Engaging multiple stakeholders in research/community based participatory research” roundtable facilitator at the 2015 American Pharmacists Association (APhA) Annual Meeting, San Diego, CA, March 2015.
- “Building sustainable PCOR partnerships with communities” presented at the University of North Carolina’s Cancer Outcomes Program Seminar, Chapel Hill, NC, March 2015.
- “Real-world treatment patterns and the uptake of biologics in elderly Medicare patients with metastatic colon cancer” (poster) presented at the ASCO 2014 Gastrointestinal Cancers Symposium, San Francisco, CA, January 2015.
- “Patient-Centered Outcomes Research Grand Rounds” presented at the Henry Ford Health System Medical Grand Rounds, Detroit, MI, November 2014.
- “Budget Impact Analysis: Applications and Design Issues” presented at the ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, November 2014. Also presented at the ISPOR 19th Annual International Meeting.
- “Patient-Centered Outcomes Research Grand Rounds” presented at the University of Maryland Department of Pediatrics Grand Rounds, Baltimore, MD, November 2014.
- “Transforming the Research Enterprise through Meaningful Patient Engagement” presented to the University of Florida CTSI, Gainesville, FL, November 2014.
- “Engaging Hard-to-Reach Patients in Patient-Centered Outcomes Research” presented at the Association for Academic Minority Physicians 27th Annual Scientific Meeting, Alexandria, VA, October 2014.
- “A Report of the ISPOR Task Force II on Budget Impact Modeling” ISPOR Educational Webinar, September 2014.
- “Case study for Patient-Centered PCTs” presented at the University of Colorado-Denver CRISP Pragmatic Trials Workshop, Denver, CO, September 2014.

- “Models for Sustaining and Expanding Patient Involvement in PCOR,” AcademyHealth-sponsored webinar as part of EDM Forum, June 2014.
- “Innovations in Engaging Patients and Caregivers in the Research Process” panel presented at AcademyHealth Annual Research Meeting, San Diego, CA, June 2014.
- “How Can We Use Randomized Trial Data to Assess Heterogeneity of Treatment Effects? Let Me Count the Ways” Panel Discussion presented at the ISPOR 19th Annual International Meeting, Montreal, Canada, June 2014.
- “What is *Value in Health* Doing for its Authors?” Forum presented at the ISPOR 19th Annual International Meeting, Montreal, Canada, June 2014.
- “Proving the Value for Oncology Therapy Using Comparative Effectiveness Research,” presented at the Fourth Annual Association for Value-Based Cancer Care Conference, Los Angeles, CA, May 2014.
- “Patient Engagement for Sustainable Partnerships with Minority Patient Communities and their Health Care Providers,” webinar to AHRQ R24 Awardees, May 2014.
- “Building Patient Partnerships with Bridges, not Helicopters” presented at the University of Michigan MICHr OPIS Symposium “Partnerships for Patient-Centered Outcomes Research,” Ann Arbor, MI, March 2014.
- “I’m a pharmacist, so aren’t I already patient-centered – what’s new?” presented at the University of Michigan, College of Pharmacy “Leading by Example” series, Ann Arbor, MI, March 2014.
- “Does first-line treatment impact the cost effectiveness of second-line treatment for elderly metastatic colon cancer patients?” (poster) presented at the ASCO 2014 Gastrointestinal Cancers Symposium, San Francisco, CA, January 2014.
- “I’m a healthcare professional so I thought I was patient centered: What’s new?” presented at the Northeastern University Bouvé Dean’s Seminar Series, Boston, MA, November 2013.
- “Patient-Centered Outcomes Research (PCOR): A Framework for Meaningful Assessment of Value” presented at the Eastern Medicaid Pharmacy Administrators Association 37th Annual Meeting, Ellicott City, MD, October 2013.
- “Setting the Stage for CER Usability: The Role of Patient Engagement” presented at the NHC/NPC meeting on “Putting Patients First®: Paving a Path to Useful CER,” Washington, DC, September 2013.
- “How Patient-Centered Outcomes Research Can Impact Use and Value of Specialty Medicine” presented at the Pittsburgh Business Group on Health meeting on “Advancing the Future of Specialty Pharmacy and Medical Management,” Pittsburgh, PA, September 2013.
- “How to Handle the Lack of Information in Emerging Markets: A List of Opportunities from Latin America” Workshop presented at the ISPOR 4th Latin American Conference, Buenos Aires, Argentina, September 2013.
- “A Framework for Meaningful Assessment of Value” presented at the MidAtlantic Business Group on Health meeting on “Specialty Rx: Understand, Identify, Manage the Cost,” Baltimore, MD, July 2013.
- “The Application of Bayesian Adaptive Designs for CER Trial” workshop presented at AcademyHealth Annual Research Meeting, Baltimore, MD, June 2013.
- “CMTP Webinar on Community-Based Participatory Research: Lessons for Stakeholder Engagement in Patient Centered Outcomes Research” AHRQ-sponsored webinar, June 2013.
- “Meet the Editors of *Value in Health*” Panel Discussion presented at the ISPOR 18th Annual International Meeting, New Orleans, LA, May 2013.
- “Stakeholder Engagement in Patient-Centered Outcomes Research: High Touch or High Tech?” Panel Discussion presented at the ISPOR 18th Annual International Meeting, New Orleans, LA, May 2013.
- “Incorporating Patient-Centered Outcomes within Comparative Effectiveness Research: Implications for Clinical Practice, Health Care Policy and Student’s Career Paths” Panel

- Discussion presented at the ISPOR 18th Annual International Meeting, New Orleans, LA, May 2013.
- “Financial Impact/Cost of Illness” Workshop presented at the ISPOR 18th Annual International Meeting, New Orleans, LA, May 2013; also presented at the 10th through 17th Meetings.
- “Patient Differences: Biologic and Non-Biological Factors” presented at the NPC Conference on *The Myth of Average: Why Individual Patient Differences Matter*, Washington, DC, November 2012.
- “Budget Impact Analysis for Rare Diseases” presented at the ISPOR-Colombia Chapter Congress II, Bogota, Colombia, November 2012.
- “Presenting Results to Payers” presented at the ISPOR-Colombia Chapter Congress II, Bogota, Colombia, November 2012.
- “Good Practices for Publishing/Manuscript Writing for Health Economics Studies” Workshop presented at the ISPOR-Colombia Chapter Congress II, Bogota, Colombia, November 2012.
- “Cost Estimation and Assessing Financial (Budget) Impact of New Health Care Technologies” Workshop presented at the ISPOR 15th Annual European Congress, Berlin, Germany, November 2012; also presented at 6th through 14th Congresses.
- “Frequency of Second and Third Line Treatment among Elderly Medicare Stage 4 Colon Cancer Patients” (poster) presented at the 37th European Society of Medical Oncology (ESMO) Conference, Vienna, Austria, October 2012.
- “Patient-Centered Outcomes Research (PCOR) with Hard-to-Reach Patients and Consumers” presented at the University of Florida, Gainesville, FL, October 2012.
- “Comparative Effectiveness Research (CER) for Health Intervention Assessments and Improving Health” presented at the National Taiwan University, Taipei, Taiwan, September 2012.
- “Conducting Oncology Health Services Research and Comparative Effectiveness Research Using Large Claims Databases: Taiwanese and United States Experiences” workshop presented at the ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan, September 2012.
- “Ensuring input from hard-to-reach consumers” presented at the Consumers United for Evidence-based Healthcare (CUE) Annual Meeting, Washington, DC, June 2012.
- “Rehospitalization and Costs among Patients Treated with Linezolid versus Vancomycin following Hospitalization for Pneumonia in the Real-World Setting” (poster) presented at the ISPOR 17th Annual International Meeting, Washington, DC, June 2012.
- “Comparative Effectiveness Research: Methods and Applications” workshop presented at the ISPOR 17th Annual International Meeting, Washington, DC, June 2012.
- “Integrating patients’ voices in study design elements with a focus on hard-to-reach populations” presented at the PCORI Workshop on Incorporating the Patient Perspective into Patient Centered Outcomes Research, Baltimore, MD, March 2012.
- “Re-hospitalization and Direct Medical Costs Among Patients Treated with Linezolid (LZD) versus Vancomycin (VAN) Following Hospitalization for Complicated Skin and Skin Structure Infections (cSSSI)” (poster) presented at the Infectious Diseases Society of America 49th Annual Meeting, Boston, MA, October 2011.
- “Bayesian Clinical Trials: Using Priors and Planning for Post-Regulatory Translation” Session Chair at the 9th International Conference on Health Policy Statistics, Cleveland, OH, October 2011.
- “Cost-Effectiveness Analysis with and Without the QALY,” presented at the Center for medical Technology Policy (CETP) CER Institute, Santa Fe, NM, July 2011.
- “Introduction and Overview: Reflections on the Importance of CER Methods Training – The Academic Perspective,” presented at the Center for medical Technology Policy (CETP) CER Institute, Santa Fe, NM, July 2011.
- “Impact of VTE on Mortality” (poster) presented at the American Society of Clinical Oncology (ASCO) 47th Annual Meeting, Chicago, IL, June 2011.

- “Experimental vs. Observational Studies: Which should have a Higher Rank in Health Care Decisions” Issue Panel presented at the ISPOR 16th Annual International Meeting, Baltimore, MD May 2011.
- “How Can Patient-Reported Outcomes become a Part of Comparative Effectiveness Research” Issue Panel Chair presented at the ISPOR 16th Annual International Meeting, Baltimore, MD May 2011.
- “Webinar and Report on Comparative Effectiveness Research Aimed at Research Advocates” webinar presented to the Research Advocacy Network, February 2011.
- “PROs in CER: A Case Study in Oncology” presented at CBI’s 4th Annual Comparative Effectiveness Research Summit & CBI’s 7th Patient Reported Outcomes Conference, Prague, Czech Republic, November 2010.
- “Pharmacoeconomics and Value Assessments of Drugs and Biomarkers” presented at the 8th annual CMOD Biomarkers meeting on Science, Economics and the Globalization of Healthcare, Bethesda, MD, September 2010.
- “Baltimore Community Health Partnership: A Model for Local Empowerment” presented at the ISHIB 25th Annual International Interdisciplinary Conference, Washington, DC, July 2010.
- “Incidence of diagnosed VTE among elderly Americans in the year following stage III or IV colon cancer diagnosis” (poster) presented at the American Society of Clinical Oncology (ASCO) 46th Annual Meeting, Chicago, IL, June 2010.
- “Pragmatic Clinical Trials - How Broad is Too Broad and How Early if Too Early?” Moderator for Issue Panel presented at the ISPOR 15th Annual International Meeting, Atlanta, GA May 2010.
- “Selecting Comparators and Outcomes for Comparative Effectiveness Studies in Oncology” Workshop presented at the ISPOR 15th Annual International Meeting, Atlanta, GA May 2010.
- “Community Health Partnership: A Model for Local Empowerment” presented at the National Minority Quality Forum’s 7th Annual Leadership Summit, Washington, DC, April 2010.
- “Evidence-based Medicine & Health Technology Assessment: Moving from Separate Appraisals to Synergistic Communications,” Program Chair for Drug Information Association Workshop, Washington, DC, March 2010.
- “Evidence Based Medicine: Trials and Tribulations,” Tutorial at the Drug Information Association 21st Annual Workshop on Medical Communications, Phoenix, AZ, March 2010.
- “Comparative effectiveness of FOLFOX and FOLFIRI versus 5FU/LV among elderly stage IV colon cancer patients” (poster) presented at the ASCO 2010 Gastrointestinal Cancers Symposium, Orlando, FL, January 2010.
- “How Comparative Effectiveness Research is Transforming Pharmaceutical and Device R&D and promotion,” Webinar Moderator for the Drug Information Association sponsored webinar, November 2009.
- “Linezolid vs. Vancomycin: Re-hospitalization Rates among Patients with Pneumonia, Staphylococcal Infection, and Skin and Soft Tissue Infection” (poster) presented at the IDSA 47th Annual Meeting, Philadelphia, PA, October 2009.
- “The Policy Perspective: The subtle and not-so-subtle influences on physician prescribing – impact of insurance and payers through formularies, guidelines, and quality measures” lecture provided at Johns Hopkins Medical School, Baltimore, MD, October 2009.
- “Assessing Costs of New Drugs and Health Technologies: The Importance of Budgetary Impact In Addition to Cost-Effectiveness Analysis” presented at the Colegio Mexicano de Famacoeconomía e Investigación, A. C. V Reunion de Farmacoeconomía, Juriquilla, Querétaro, Mexico, April, 2009.
- “Describing and Researching Health Disparities – The Role of Communities and Partnerships: Health Disparities and the Role of Services Research in the Community” presented at the Third Annual Health Disparities Conference, New Orleans, LA, April 2009.
- “Pharmacoeconomics Fulbright Senior Specialist Program” presented at the University of Galway, Galway, Ireland, March 2009.

- “Trends in Health Disparities in Staging of Prostate cancer Patients” (poster) presented at the ASCO 2009 Genitourinary Cancers Symposium, Orlando, FL, February 2009.
- “Medical Decision-Making: The Payer Perspective” lecture provide at Johns Hopkins Medical School, Baltimore, MD, February 2009.
- “Budget Impact Analysis: An Overview” presented at the ISPOR Mexico Chapter Annual Meeting, Mexico City, Mexico, December 2008.
- “Trends in Health Disparities in Staging of Prostate cancer Patients” guest seminar presented at the University of Rhode Island, Kingston, RI, November 2008; also presented at the University of Southern California, Los Angeles, CA, December 2008.
- “Trends in Health Disparities in Staging of Prostate cancer Patients” presented at the Association for Academic Minority Physicians Annual Meeting, Naples, FL, October 2008.
- “Evidence-Based Medicine and Health Technology Assessment: Can We Find Common Ground,” Conference Chair for the Drug Information Association, Alexandria, VA, September 2008.
- “Unequal Health Burden,” presented at the American Cancer Society Cervical Cancer Conference: Tipping the Scales, Better Health for Generations of Women, Research Triangle Park, NC, August 2008.
- “Disparities and Trends in Prostate Cancer Screening Over Time” (poster) presented at the American Society of Clinical Oncology (ASCO) 44th Annual Meeting, Chicago, IL, May 2008.
- Conference co-Chair for the ISPOR 13th Annual International Meeting, Toronto, ON, Canada, May 2008.
- “Building a Research Agenda: A Case Study in Health Disparities in End Stage Renal Disease (ESRD)” presented at the University of Tennessee School of Pharmacy, Memphis, TN, April 2008.
- “The Future of Pharmacoeconomic Analyses: How Can We Best Evaluate Advanced Therapeutic and Preventive Options” presented at an AMCP Satellite Symposium, San Francisco, CA, April 2008.
- “Debate: The Pros and Cons of ePROs” presented at the DIA Annual Meeting, Atlanta, GA, June 2007.
- “The Economic Implications of New Episodes of MDD for Non-stable Versus Stable Depression” (poster) presented at the American Psychiatric Association’s 160th Annual Meeting, San Diego, CA May 2007.
- “Probability of Increase in Healthcare Costs in Non-Stable Depressed Individuals Compared to Stable Patients” (poster) presented at the American Psychiatric Association’s 160th Annual Meeting, San Diego, CA May 2007.
- “Predicting the Budgetary Impact of New Drugs: Applying Microeconomic Theory and Case Studies” Workshop presented at the ISPOR 12th Annual International Meeting, Crystal City, VA, May 2007.
- “Quality Issues Related to the Use of Patient Level Databases” Workshop presented at the ISPOR 12th Annual International Meeting, Crystal City, VA, May 2007.
- “Formulary Applications in Translational Medicine” Workshop presented at the ISPOR 12th Annual International Meeting, Crystal City, VA, May 2007.
- “Manuscript Writing and the Peer-Review Process” Forum presented at the ISPOR 12th Annual International Meeting, Crystal City, VA, May 2007.
- “Value-based Decision Making: US Perspectives” presented at the Alzheimer’s Association Research Roundtable: Health Economics and Real World Value of Therapy in Alzheimer’s Disease Conference, Washington, DC, November 2006.
- “Introduction to Global Health Economics” presented at the Alzheimer’s Association Research Roundtable: Health Economics and Real World Value of Therapy in Alzheimer’s Disease Conference, Washington, DC, November 2006.
- “Health Disparities in the 21st Century” Keynote Address presented at the ACCP Annual Meeting, St. Louis, MO, October 2006.

- “Pharmacoconomics Fulbright Senior Scholar Program – Part 2” presented at the Universidad de Montevideo, Montevideo, Uruguay, October 2006.
- “Case Studies of New and Specialty Pharmaceuticals” presented at the Society of Actuaries’ “Maximizing the Value of the Pharmacy Benefit” Seminar, Chicago, IL, July 2006.
- “Rapid Cycle Research Based in Organized Health Care Delivery Systems” presented at the AcademyHealth 2006 Annual Research Meeting, Seattle, WA, June 2006.
- “Initial Dose and Persistence for Five Major Atypical Antipsychotic Agents in Medicaid Enrollees” (poster) presented at the American Psychiatric Association’s 159th Annual Meeting, Toronto, Canada, May 2006.
- “Continuous Enrollment and the Incomplete Information Tradeoff” Workshop presented at the ISPOR 11th Annual International Meeting, Philadelphia, PA, May 2006.
- “Formulary Decisions for Medicare Part D” Workshop presented at the ISPOR 11th Annual International Meeting, Philadelphia, PA, May 2006.
- “Incorporating Compliance Measures in Retrospective Cost Studies” Workshop presented at the ISPOR 11th Annual International Meeting, Philadelphia, PA, May 2006.
- “Starting Dose and Persistence for Ziprasidone Users in Medicaid” (poster) presented at the Association of European Psychiatrists’ 14th European Congress of Psychiatry, Nice, France, March 2006.
- “Budget Impact Modeling: Appropriateness and Determining Quality Input,” presentation to ISPOR Student Chapters” as an ISPOR educational teleconference, February, 2006.
- “Factors Influencing Ziprasidone Prescribed Doses among Medicaid Patients with Schizophrenia” (poster) presented at the ISPOR 8th Annual European Congress, Florence, Italy, November 2005.
- “Major GI Events among Cox-2 Inhibitor, NSAID, and Aspirin Users” (poster) presented at the American College of Gastroenterology Meeting, Honolulu, HI, October 2005.
- “Pharmacoconomics Fulbright Senior Scholar Program – Part 1” presented at the Universidad de Montevideo, Montevideo, Uruguay, October 2005.
- “Pharmacoconomics” at the Johns Hopkins Bloomberg School of Public Health’s Twenty-Third Annual Graduate Summer Institute of Epidemiology and Biostatistics: Pharmacoepidemiology summer course” at the, Baltimore, MD, June 2005.
- “Starting Dose and Persistence for Ziprasidone Users in Medicaid” (poster) presented at the American Psychiatric Association’s 158th Annual Meeting, Atlanta, GA May 2005.
- “Assessment of the Impact of Valdecoxib on Systolic Blood Pressure in Clinical Practice” (poster) presented at the American Society of Hypertension Twentieth Annual Scientific Meeting, San Francisco, CA May 2005.
- “Formulary Decisions: Assessing Harm, Showing Benefit, Proving Value, From Managed Care Data” Workshop presented at the ISPOR 10th Annual International Meeting, Washington, DC, May 2005.
- “The Peer Review Process: How Editors Draw the Line Between Science and Advertising” Issues Panel presented at the ISPOR 10th Annual International Meeting, Washington, DC, May 2005.
- “Starting Dose and Persistence for Ziprasidone Users in Medicaid” (poster) presented at the ISPOR 10th Annual International Meeting, Washington, DC, May 2005.
- “Triptans for Migraine Therapy: A Comparison Based on Number Needed to Treat and Doses Needed to Treat” (poster) presented at the ISPOR 10th Annual International Meeting, Washington, DC, May 2005.
- “Cost-Effectiveness of Eletriptan versus Zolmitriptan: results from a Randomized Controlled Trial” (poster) presented at the ISPOR 10th Annual International Meeting, Washington, DC, May 2005.
- “Science or Advertising: How Editors Draw the Line” Issues Panel presented at the ISPOR 7th Annual European Congress, Hamburg, Germany, November 2004.
- “Disparities in Medicaid Cancer Expenditures” (poster) presented at the ISPOR 7th Annual European Congress, Hamburg, Germany, November 2004.

- “Pharmacoconomics/Outcomes Research Mini Course” presented at the Universidad de Montevideo, Montevideo, Uruguay, October, 2004.
- “The Economic Impact of Laparoscopic Kidney Retrieval on the Medicare Program” presented at a Congressional Staff briefing on *Organ Transplant Issues*, Washington, DC June 2004.
- “Cost Effectiveness of Kidney Transplantation” presented at the University of Cincinnati School of Pharmacy Graduate Research Seminar Series, Cincinnati, OH, May 2004.
- “The Formulary Decision Process: What Kind of Information is Truly Helpful?” Workshop presented at the ISPOR 9th Annual International Meeting, Arlington, VA, May 2004.
- “Managed Care Data: Tools and Metrics for Formulary Development” Workshop presented at the ISPOR 9th Annual International Meeting, Arlington, VA, May 2004.
- “Economic Analysis - Financial Impact/Cost of Illness” Workshop presented at the ISPOR 9th Annual International Meeting, Arlington, VA, May 2004.
- “Comparison of First Refill Rates Among Branded SSRI Users” (poster) presented at the American Psychiatric Association’s 157th Annual Meeting, New York, NY May 2004.
- “Translating Clinical Outcomes into Economic Outcomes” presented at the University of Iowa School of Pharmacy Graduate Research Day, Iowa City, IA, April 2004.
- “Translating Clinical Outcomes into Economic Outcomes” presented at IIR’s 2nd Annual Outcomes Research Conference on *Closing the Gap between Drug Manufacturers and Customers*, Washington, DC, February 2004.
- “The Impact of Pharmacogenomics on the Cost-Effectiveness Ratio,” presented at the Southern Economic Association 73rd Annual Meeting, San Antonio, TX, November 2003.
- “The Changing Landscape of Dyslipidemia: Emerging Approaches to Achieving Lower Lipoprotein Targets - Pharmacoeconomic Outcomes for Treating Dyslipidemia” presented at the Academy of Managed Care Pharmacy’s 2003 Educational Conference, Montreal, Canada, October 2003.
- “The AMCP Format for Formulary Submissions: Collecting and Evaluating Cost-Effectiveness and Budget Impact Information” presented at the Academy of Managed Care Pharmacy’s 2003 Educational Conference, Montreal, Canada, October 2003.
- “Demystifying Pharmacoeconomics for the Practitioner” presented at the Academy of Managed Care Pharmacy’s 2003 Educational Conference, Montreal, Canada, October 2003.
- “Racial Disparities in Smoking and Clinical Trials Knowledge and Participation” presented at Howard University College of Pharmacy Graduate Seminar, Washington, DC, October 2003.
- “Pharmacoconomics/Outcomes Research Mini Course” presented at Chulalongkorn University, Bangkok, Thailand, August 4 - 14, 2003.
- “Outcomes Research for Everyone Else: A Primer for the Non Outcomes Researcher” Tutorial at the DIA 39th Annual Meeting, San Antonio, TX, June 2003.
- “From Good to Blockbuster: Successes in Outcomes Research” Session Chair at the DIA 39th Annual Meeting, San Antonio, TX, June 2003.
- “Demystifying Pharmacoeconomics for the Practitioner” presented at the American Society of Health-System Pharmacists’ 2003 Summer Meeting, San Diego, CA, June 2003.
- “Cost estimation and Assessing Financial (Budget) Impact of New Health Care Technologies” Workshop presented at the ISPOR 8th Annual International Meeting, Arlington, VA, May 2003.
- “Risk Management: Implications for Formulary Decision-Making from Risk-Benefit to Cost Effectiveness” Workshop presented at the ISPOR 8th Annual International Meeting, Arlington, VA, May 2003.
- “The Societal Benefits and Costs of the 4th Hurdle: The European Experience - Evidence of the Impact on the Pharmaceutical Industry” Plenary Talk presented at the ISPOR 5th Annual European Conference, Rotterdam, The Netherlands, November 2002.
- “Multi-Country Comparison of Hypertension Costs from Hospitalizations and Ambulatory Care” presented at the ISPOR 5th Annual European Conference, Rotterdam, The Netherlands, November 2002.
- “Sinusitis-Related Provider and Patient Burden” presented at the DIA 4th Annual Pharmaceutical Outcomes Research Meeting, Newport, RI, October 2002.

- “Pharmacoconomics and Outcomes Research: Issues in Study Design, Analysis and Interpretation” presented at Howard University College of Pharmacy Preceptor Recognition Event, Washington, DC, September 2002.
- “Outcomes Research for Everyone Else: A Primer for the Non Outcomes Researcher” Tutorial at the DIA 38th Annual Meeting, Chicago, IL, June 2002.
- “From Good to Blockbuster: Successes in Outcomes Research” Session Chair at the DIA 38th Annual Meeting, Chicago, IL, June 2002.
- “Communicating Pharmaceutical Value” presented at the DIA 38th Annual Meeting, Chicago, IL, June 2002.
- “Pharmaceutical Costs, Expenditures, and Policy Implications” Breakfast with the Experts presented at the ISPOR 7th Annual International Meeting, Crystal City, VA, May 2002.
- “Careers in Academia, Consulting, Government and Industry: A View from the Ivory Towers” ISPOR Student Forum presented at the ISPOR 7th Annual International Meeting, Crystal City, VA, May 2002.
- “Incidence or Prevalence: Implications for Formulary Decision-Making” Workshop presented at the ISPOR 7th Annual International Meeting, Crystal City, VA, May 2002.
- “Healthcare Financing in the 21st Century: Cost Implications for Employers, Insurers, and Policy Makers” CDPP Conference Chair, Washington, DC, April 2002.
- “A Comparison of Flow of Funds for Treatment of ESRD by Treatment Modalities” (poster) presented at the American Transplant Congress 2002 Meeting, Washington, DC, April 2002.
- “Communicating Pharmaceutical Value” presented at the DIA 13th Annual Workshop for Medical Communications, Tampa, FL, March 2002.
- “Arthritis Economic Decision-Making for Drug Therapies” presented at The Maryland Academy of Family Physicians conference on *The Arthritis Connection: Promising Trends and Perspectives*, Baltimore, MD, February 2002.
- “Regulation of Drug Prices” presented at the University of Arizona’s 10th Annual Invitational Conference - Pharmaceutical Costs: The Debate Continues, Tucson, AZ, January 2002.
- “The Impact of Pipeline Drugs on United States Drug Expenditure Growth Trends” presented at the ISPOR 4th Annual European Conference, Cannes, France, November 2001.
- “Pharmacoconomic and Quality of Life Labeling and Promotional Claims: A Global Update” DIA Workshop Chair, Philadelphia, PA, October 2001.
- “Outcomes Issues for Regulatory Professionals” Tutorial at the DIA workshop on Pharmacoconomic and Quality of Life Labeling and Promotional Claims: A Global Update, Philadelphia, PA, October 2001.
- “The Cost on the Healthcare System” presented at The MediMedia Managed Care conference on *Best Practice Guidelines & Current Treatment Trends for Improving Hypercholesterolemia Risk Reduction*, St. Louis, MO, August 2001.
- “Arthritis Economic Decision-Making for Drug Therapies” presented at The Arthritis Foundation/NAMCP/ACMCM conference on *The Arthritis Connection: Promising Trends and Perspectives*, Virginia Beach, VA, July 2001.
- “Outcomes Research for Everyone Else: A Primer for the Non Outcomes Researcher” Tutorial at the DIA Annual Meeting, Denver, CO, July 2001.
- “From Good to Blockbuster: Successes in Outcomes Research” Session Chair at the DIA Annual Meeting, Denver, CO, July 2001.
- “Cost of Treatment for AAT-Deficiency” presented at the Alpha-1 Foundation 3rd International Scientific Conference, Warrenton, VA, June 2001.
- “Challenges in Performing Meta Analysis in Heart failure Outcomes Research” Workshop presented at the ISPOR 6th Annual International Meeting, Crystal City, VA, May 2001.
- “Comparability of Published Studies on Cost-Effectiveness of Antihypertensive Therapy: Do the Results Help the Decision-Making Process?” (poster) presented at the ISPOR 6th Annual International Meeting, Crystal City, VA, May 2001.
- “Pharmacoconomics: Optimizing the Use of Data” Institute for International Research Conference Chair Philadelphia, PA, March 2001.

- “Building Pharmacoeconomic Models that Address Decision-Makers' Concerns” presented at IIR's Conference on *Pharmacoeconomics: Optimizing the Use of Data*, Philadelphia, PA, March 2001.
- “Exploring Decisions about Formulary Adoption and Clinical Pathways/Guidelines” presented at IIR's Conference on *Pharmacoeconomics: Optimizing the Use of Data*, Philadelphia, PA, March 2001.
- “Merging Marketing and Clinical Development” DIA Workshop Program Committee, Philadelphia, PA, March 2001.
- “Pharmaceutical Market Impact of the Early 1990s Health Care Debate” presented at the Midwest Business Administration Association/Business & Health Administration Association Annual Meeting, Chicago, IL, March 2001.
- “Predicting Future Drug Expenditures: Where Are We Headed and Can We Do Anything About It?” presented at IIR's 2nd Annual National Forum on *Controlling Escalating Pharmacy Benefit Costs*, Atlanta, GA February 2001.
- “Pharmacogenomics: Methodological Considerations for Evaluating Outcomes and Cost Effectiveness” presented at the University of Arizona's 9th Annual Invitational Conference - Pharmacogenomics: Implications for Patients, Providers, Policy and Payers, Tucson, AZ, January 2002.
- “Analysis of an Osteoporosis Model” presented at the Department of Obstetrics and Gynecology at UCLA and the UCLA/Harbor OB/GYN Collegium Conference on *A Pharmacoeconomic Approach to Clinical Decision-Making for the Menopause*, Los Angeles, CA December 2000.
- “Modeling the Annual Cost of Postmenopausal Osteoporosis Treatment Using Raloxifene, Bisphosphonates, or Calcitonin” (poster) presented at the 35th Annual ASHP Midyear Clinical Meeting, Las Vegas, NV, December 2000.
- “Justifying Product Value with Indirect Costs: An Application to Migraine” Workshop presented at the ISPOR 3rd Annual European Conference, Antwerp, Belgium, November 2000.
- “Integrated Health Systems Delivery I: Understanding, Developing, and Documenting Integrated Patient (Pharmaceutical) Care” presented at the Thunderbird Executive Education Conference on *Leadership in Healthcare Administration for Pharmacists*, Glendale, AZ, October 2000.
- “Integrated Health Systems Delivery II: The Role of Outcomes Research” presented at the Thunderbird Executive Education Conference on *Leadership in Healthcare Administration for Pharmacists*, Glendale, AZ, October 2000.
- “Case Study: Analysis of an Osteoporosis Model” presented at a session on “A Turn-Key Approach to Utilizing Valuable Economic Models” at the AMCP 2000 Educational Conference, San Diego, CA, October 2000.
- “Pharmacoeconomic and Quality of Life Labeling and Marketing Claims” DIA Workshop Chair, New Orleans, LA, October 2000.
- “Presidential Race: Costly Pills” broadcast appearance on *The Marc Steiner Show* - 88.1 FM WJHU (local Public Radio station) Baltimore, MD, September 2000.
- “Outcomes Research for Everyone Else: A Primer for the Non Outcomes Researcher” Tutorial at the DIA Annual Meeting, San Diego, CA, June 2000.
- “From Good to Blockbuster: Successes in Outcomes Research” Session Chair at the DIA Annual Meeting, San Diego, CA, June 2000.
- “Study Design Issues in Health Economics” Session Chair at the DIA Annual Meeting, San Diego, CA, June 2000.
- “Cost-Effectiveness/Cost-Benefit Analyses (Session 2)” Session Chair at the ISPOR Annual Meeting, Arlington, VA, May 2000.
- “Employer Costs of Diabetes” presented at the BMS Employer Diabetes Health Panel, Carlsbad, CA May 2000.
- “The Impact of Pipeline Drugs on Pharmaceutical Expenditures” presented at the HIAA/BCBSA Pipeline Pharmaceuticals Symposium, Washington, DC, April 2000.

- "The Impact of Pipeline Drugs on Pharmaceutical Expenditures" presented at the HIAA/BCBSA Pipeline Pharmaceuticals Symposium, New York, NY, April 2000.
- "Outcomes Collected in Randomised Clinical Trials and Retrospective Database Studies" presented at the DIA EuroMeeting, Nice, France, March 2000.
- "Estimates of the Indirect Cost of HIV and AIDS in the United Kingdom" (poster) presented at the ISPOR EuroMeeting, Edinburgh, Scotland, November 1999.
- "Government's Role in Pharmaceutical Pricing" presented at the Drug Pricing Policy Forum, Kunming, China, October 1999.
- "Pharmaceutical Pricing and International Practice" presented at the Drug Pricing Policy Forum, Kunming, China, October 1999.
- "Cancer Screening in Maryland: A Review of the Cancer Insurance Study and Cost Related Aspects" presented at the Maryland State Council on Cancer Control: Cancer Roundtable Meeting at Johns Hopkins School of Hygiene & Public Health, Baltimore, MD, October 1999.
- "Applied Pharmacoeconomics for Formulary Decision Making" presented at the 7th Annual ASCP Mid-Atlantic Conference, Cumberland, MD, August 1999.
- "Outcomes Research for Everyone Else: A Primer for the Non Outcomes Researcher" Tutorial at the DIA Annual Meeting, Baltimore, MD, June 1999.
- "Recent Successful Launches: The Role of Outcomes Research" Session Chair at the DIA Annual Meeting, Baltimore, MD, June 1999.
- "Pharmacoeconomic Decision-Making: Observations from the Real World" presented at the DIA Annual Meeting, Baltimore, MD, June 1999.
- "Outcomes Data on Osteoporosis for Formulary Decisions" presented at the Lilly Centre for Women's Health Outcomes Symposium, Indianapolis, IN May 1999.
- "Cost-of-Treatment vs. Cost-of-Illness Analysis" presented at The Wintergreen Conference V, Wintergreen, VA, May 1999.
- "Pharmacoeconomic Evaluation of a Community Acquired Pneumonia Program" presented at the Academy of Managed Care Pharmacy's Annual Meeting, Minneapolis, MN, April 1999.
- "Impact of Community Acquired Pneumonia (CAP) Guidelines on Treatment Costs" presented at the DIA's Pharmaceutical Outcomes Research: Past, Present and Future Workshop, Seattle, WA, April 1999.
- "Alpha 1-Antitrypsin Deficiency Cost of Illness Analysis" presented at the American Thoracic Society Annual Meeting, San Diego, CA, April 1999.
- "Cost-of-Treatment Models: Tools for Comparative Cost Analyses" (poster) presented at the PhRMA Foundation Annual Awardee Meeting, New York, NY, April 1999.
- "Practical Overview of Pharmacoeconomic Research" presented at ASCP's Generating and Analyzing Data for Clinical and Business Applications Workshop, Seattle, WA, November 1998.
- "Pharmacoeconomics - A Practical Approach" presented at the Maryland Society of Health-System Pharmacists 33rd Annual Seminar, Deep Creek Lake, MD, October 1998.
- "Cost of Treatment vs. Cost of Illness Analysis: Managing Annual Budgets vs Projecting Lifetime Expenditures for your Patients" presented at the Zitter Group's 5th Annual Congress on Health Outcomes & Accountability, San Diego, CA, October 1998.
- "Pharmacoeconomics/Outcomes Research Mini Course" presented at the Clínic Barcelona, Hospital Universitari, Barcelona, Spain, September 28 - October 4, 1998.
- "Pharmacoeconomics/Outcomes Research" presented at the Regulatory Affairs Professional Society Conference on "International Clinical Trials," Newark, NJ, August 1998.
- "International Pharmacoeconomics Guidelines: Areas of Consensus and Disagreement" presented at the Regulatory Affairs Professional Society Conference on "International Clinical Trials," Newark, NJ, August 1998.
- "Outcomes Research for Everyone Else: A Primer for the Non Outcomes Researcher" Tutorial at the DIA Annual Meeting, Boston, MA, June 1998.

- “Case Study: The Health Care System Focus” presented at Howard University’s “Pharmacoconomics, Clinical Outcomes and Patient Care Seminar” Greenbelt, MD, June 1998.
- “Issues in Developing Economic Models for Managed Care: The Case of Osteoporosis Prevention” workshop presented at ISPOR’s Third Annual International Meeting, Philadelphia, PA, May 1998.
- “Practical Overview of Pharmacoconomics” presented at ASCP’s “Data...Your Competitive Edge” Workshop, Baltimore, MD, April 1998.
- “Decision Modeling in Pharmacoconomics” presented as a roundtable discussion at the APhA Annual Meeting, Miami, FL, March 1998.
- “Outcomes Research for Everyone Else...Introduction to the History, Jargon and Definitions” presented at the DIA Conference on Outcomes Research for the Non Outcomes Researcher, Baltimore, MD, March 1998.
- “Pharmacoconomic Guidelines: Areas of Consensus and Disagreement” presented at the ISPOR Conference on Pharmacoconomics: Identifying the Issues, Crystal City, VA, February 1998.
- “Pharmacoconomics of NSAIDs: Beyond Bleeds” presented at the APhA Annual Meeting, Los Angeles, CA, March 1997.
- “Economic Model of NSAID Use and Upper Gastrointestinal Symptoms” presented at the Association of Rheumatology Health Professionals National Scientific Meeting, Orlando, FL, October 1996.
- “Outcomes Research Assessment” presented at a USP Mini-Symposium, Rockville, MD, July 1996.
- “Strategic Drug Pricing in the Presence of Managed Care Competition” presented at The Wintergreen Conference IV, Wintergreen, VA, May 1996.
- “Strategic Drug Pricing in the Presence of Managed Care Competition” presented at the Southern Economic Association Annual Meeting, New Orleans, LA, November 1995.
- “Unintended Consequences of Medicaid Rebates” presented at the DIA Annual Meeting, Orlando, FL, June 1995.
- “The Appropriate Setting for Measurements in Pharmacoconomic Evaluations” presented at CePOR Conference, Chapel Hill, NC, April 1995.
- “Medicaid Drug Rebates, Pharmaceutical Prices and Unintended Consequences of Health Policy Reform” presented at the Glaxo Career Development Awards Convocation, Durham, NC, March 1995.
- “Medicaid Drug Rebates, Pharmaceutical Prices, and Unintended Consequences of OBRA 1990” presented at The Wintergreen Conference III, Wintergreen, VA, October 1994.
- “The Interface of Methodologies from Epidemiology and Economics,” presented at the American Association of Colleges of Pharmacy Annual Meeting, Albuquerque, NM, July 1994.
- “Pharmaceutical Managed Care: A Penny Saved is a Penny Earned,” poster presentation at the American Pharmaceutical Association Annual Meeting, Seattle, WA, March 1994.
- “Most-Favored-Customer Protection and Medicaid Rebates under OBRA 1990,” presented at the Southern Economic Association Annual Meeting, New Orleans, LA, November 1993.

SERVICE ACTIVITIES - UNIVERSITY OF MARYLAND (UMB) SCHOOL OF PHARMACY

ASCP Student Chapter Faculty Advisor	1998 – 2001
Admissions Committee – PharmD (Committee Chair 2013-2014)	2011 - 2014
ISPOR Student Chapter Faculty Advisor	2002 - 2015
UMB A Bridge to academic Excellence Tutor	2001
UMB Assessment Focus Group	1995, 1996
UMB Community Outreach Partnership Centers Committee	1997
UMB Computer Working Group	2000-2003
UMB Curriculum Committee	1996, 1997, 2008
UMB ELP Committee	2008
UMB Faculty Affairs Committee	1999-2001
UMB Faculty Development Committee	1997
UMB Faculty Senator	1997 - 1999
UMB PHSR Graduate Program Director	1998 - 2003
UMB PPS Research Committee	1998 - 2003
UMB Professional Reimbursement Committee	1998
UMB Research and Graduate Education Committee (ad hoc)	1998 - 2002
UMB Research and Graduate Education Committee Chair	2002 - 2003
UMB Various Faculty Search Committees	1997 - present

SERVICE ACTIVITIES - EXTERNAL

AcademyHealth 2018 Annual Research Meeting (ARM) theme co-leader of the “Patient-Centered Research” theme	2018
AHRQ Ad hoc Reviewer	2004, 2008 to 2012
AHRQ Healthcare Research Training (HCRT) Study Section	2013 – 2019
AHRQ Health Systems Research (HSR) Study Section	2005 – 2007
AHRQ Expert Meeting on Evidence Evaluation for Assignment of HCPCS Codes	2007
APHA Annual Meeting Abstract Reviewer	1997
APhA Annual Meeting Abstract Reviewer	1996, 1999, 2000, 2002
ASCP Pharmacoeconomic Fellowship Selection Panel	1996
ASCP Advisory Panel for ASCP Fleetwood Project	1995 – 1999
Cancer Care Ontario Grant Reviewer	2011
DIA Annual Meeting Planning Committee - EBM Section Chair	2006-2009
DIA - IMPACT SIAC Chair	2008-2010
DIA Research Grant Award Program Committee Member	2001
DIA Steering Committee of the Americas Vice Chair	2000-2001
DIA Steering Committee of the Americas Programming Chair	2002-2004
Institute for Medicaid Innovation Advisory Board	2017-2019
ISPOR Awards Committee Chair	2004-2006
ISPOR BIA Task Force Committee Member	2006
ISPOR Real World Data Task Force Sub-Committee Chair	2006
ISPOR Drug Costs in Pharmacoeconomic Studies Sub-Committee Chair	2007 - 2008
ISPOR 13 th Annual International Meeting co-Chair	2008
ISPOR Student Chapter Faculty Advisor Council Chair	2009-2011
Maryland Public Health Association (MPHA) Board Member	1996 - 2001
MPHA Treasurer	1998 - 2000
National Academy of Medicine “Stakeholder Support and Demand for Health Data Sharing Initiative” Steering Committee Member	2018-2019
NIH/NCI Ad hoc Reviewer	2008 - 2011
NIH/NCI Study Section J Committee Member	2011 - 2015
NIH/NHLBI Ad hoc Reviewer	1997, 1998
Maryland Health Care Commission Hospital and Ambulatory Surgical Facility Report Card Steering Committee Member	2000- 2002

Maryland Health Care Commission Hospital Performance Guide

Steering Committee Member

2002- 2006

PhRMA Foundation Health Outcomes Research Grants Committee Member

2008 - 2016

PCORI Patient-Powered Research Networks B Study Section Chair

2013

PCORI Methods Study Section Chair

2014-2017

JOURNAL REVIEWS

<i>American Journal of Geriatric Pharmacotherapy</i> , Reviewer	2005
<i>American Journal of Hypertension</i> , Reviewer	2004
<i>American Journal of Pharmaceutical Education</i> , Reviewer	1997 – 2002
<i>American Journal of Pharmacy Benefits</i> , Reviewer	2010 – 2015
<i>American Journal of Transplantation</i> , Reviewer	2004
<i>American Journal of Managed Care</i> , Reviewer	1999 - present
<i>Annals of Internal Medicine</i> , Reviewer	2011
<i>Arthritis Care & Research</i> , Reviewer	2006
<i>Cancer Investigation</i> , Reviewer	2008
<i>Cancer</i> , Reviewer	2010 - present
<i>Chest</i> , Reviewer	2007 - 2011
<i>Clinical Drug Investigation</i> , Reviewer	2000, 2004
<i>Clinical Epidemiology</i> , Reviewer	2018
<i>Clinical Therapeutics</i> , Section Editor	2000 - 2010
<i>Clinical Therapeutics</i> , Reviewer	1999 - 2012
<i>Clinical Trials: Journal of the Society for Clinical Trials</i> , Reviewer	2016
<i>Contemporary Economic Policy</i> , Reviewer	2002
<i>Current Therapeutic Research</i> , Reviewer	2002 - 2011
<i>Disease Management & Health Outcomes</i> , Reviewer	2001 - 2003
<i>Drugs & Aging</i> , Reviewer	2002
<i>Health Affairs</i> , Reviewer	1997 - present
<i>Health Economics</i> , Reviewer	2003, 2010
<i>Health Policy</i> , Reviewer	2007
<i>Health Services Research</i> , Reviewer	1998, 2012
<i>Inquiry</i> , Reviewer	2001
<i>Journal of Comparative Effectiveness Research</i> , Reviewer	2015 - present
<i>Journal of Clinical Epidemiology</i> , Reviewer	2012
<i>Journal of Health Expectations</i> , Reviewer	2018
<i>Journal of Health Politics, Policy and Law</i> , Reviewer	1997, 2003, 2004
<i>Journal of Managed Care & Specialty Pharmacy</i> , Reviewer	2002 - present
<i>Journal of Managed Care Medicine, Genomics & Biotech</i> , Reviewer	2008, 2009
<i>Journal of the National Cancer Institute</i> , Reviewer	2014, 2018
<i>Journal of the National Medical Association</i> , Reviewer	2003 - 2008
<i>Journal of Pharmacy Teaching</i> , Reviewer	1994 - 2002
<i>Medical Care</i> , Supplemental Issue Reviewer	1995, 2008
<i>Milbank Quarterly</i> , Reviewer	2007- 2015
<i>Nature Clinical Practice Oncology</i> , Reviewer	2007
<i>Osteoporosis International</i> , Reviewer	2002
<i>PharmacoEconomics</i> , Reviewer	1995 - present
<i>PharmacoEconomics</i> , Editorial Advisory Board	2002 - 2011
<i>Research in Social & Administrative Pharmacy</i> , Reviewer	2011
<i>Science</i> , Reviewer	2000
<i>Seminars in Arthritis and Rheumatism</i> , Reviewer	2018
<i>Social Science & Medicine</i> , Reviewer	2004
<i>Treatments in Respiratory Medicine</i> , Reviewer	2004
<i>Value in Health</i> , Editorial Board	1998 - 2001
<i>Value in Health</i> , co-Editor	2002 - 2010
<i>Value in Health</i> , co-Editor-in-Chief	2010 to present

CONSULTING/ADVISORY BOARDS (WITHIN LAST 3 YEARS)

Bayer Pharmaceuticals

Boehringer-Ingelheim

Illumina

Janssen/J&J

Merck

Pfizer

Regeneron

Sanofi